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Obesity and cardiovascular disease is common in bipolar disorder, both of which are 
associated with insulin resistance.  Insulin resistance is also associated with distribution of body 
fat, specifically abdominal visceral fat and fat accumulation in skeletal muscle.  Furthermore, 
reduced capacity to utilize fat has been linked with obesity, type 2 diabetes and insulin resistance.  
PURPOSE: To compare insulin sensitivity, body composition and resting substrate utilization 
between obese and normal weight patients with bipolar 1 disorder and race, age and BMI matched 
controls.  METHODS:  Participants underwent dual energy X-ray absorptiometry (DEXA) to 
measure fat mass (FM) and fat-free mass (FFM), computed tomography (CT) to measure cross-
sectional abdominal adipose tissue and indirect calorimetry to measure resting substrate oxidation.  
Free- living energy expenditure was measured for 5 days using BodyMedia SenseWear Pro 
Armband and the food frequency questionnaire estimated the usual consumption of 79 main food 
items over the preceding 12 months.  Insulin sensitivity was measured from fasting insulin and 
glucose measurements and defined by the homeostatic model assessment of insulin resistance 
(HOMA IR).  RESULTS:  Eighteen patients with bipolar 1 disorder and 17 controls participated 
in this study.  There were no differences observed in insulin resistance between obese (BMI>30 
kg/m2) patients and controls (56.8 ± 17.2 vs. 51.8 ± 11.1; P = 0.842) or normal weight (BMI<25 
kg/m2) patients and controls (30.5 ± 6.3 vs. 27.0 ± 5.7 P = 0.691).  CT revealed a difference in total 
abdominal fat (718.1 ± 33.6 vs. 607.4 ± 38.6cm2; P = 0.04), a trend in visceral abdominal fat (P = 
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0.06) though no difference in subcutaneous abdominal fat between obese patients and controls.  
Indirect calorimetry revealed a trend (P=0.06) in reduced fat oxidation in normal weight patients 
compared to controls and when combining obese and normal weight patients.  CONCLUSION:  
Patients with bipolar 1 disorder do not appear to be more insulin resistant than controls after 
accounting for their obesity.  However, a reduced fat oxidation in normal weight patients may be 
an underlying factor predisposing them for future weight gain and concomitant increased risk for 
type 2 diabetes.   
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1.0  INTRODUCTION 
Insulin resistance has been linked to diabetes, hypertension, dyslipidemia and 
cardiovascular disease.  Obesity is a common thread among metabolic disorders (Reilly and 
Rader 2003) as well as cardiovascular disease (Haffner 1997; Lempiainen, Mykkanen et al. 1999) 
and is associated with insulin resistance.(Goodpaster, Thaete et al. 1997)  In addition to 
generalized obesity by either body fat or body mass index (BMI) criteria, insulin resistance is 
also associated with the distribution of body fat, including abdominal visceral fat (Goodpaster, 
Thaete et al. 1997) and fat accumulation within skeletal muscle.(Goodpaster, Thaete et al. 2000)  
There is also increasing evidence that impaired capacity for fat oxidation in obesity and type 2 
diabetes is related to insulin resistance.(Kelley, Goodpaster et al. 1999)  Thus, the metabolic 
disturbances of insulin resistance and type 2 diabetes appear to be more global to include 
dysregulated fat metabolism as well as impaired glucose metabolism. 
1.1 OBESITY 
The alarming increase in obesity in the U.S. (Mokdad, Ford et al. 2003) and around the 
world (Hernandez, Cardonnet et al. 1987; al-Isa 1995; Hodge, Dowse et al. 1995; Flegal, Carroll 
et al. 1998; Arroyo, Loria et al. 2000) is a paramount public health concern affecting children, 
middle-aged and older men and women across a variety of ethnic and racial groups.  The 
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increase in obesity has led to a marked increase in the metabolic syndrome (Ford, Giles et al. 
2002) creating additional risks for type II diabetes and cardiovascular disease.  Data from the 
Framingham study have established an increased incidence of cardiovascular events with 
increasing weight (Hubert, Feinleib et al. 1983; Colditz, Willett et al. 1995) and weight gain was 
a significant risk factor for development of diabetes.   The association of obesity with the insulin 
resistance syndrome is not only related to the degree of obesity but is dependent on body fat 
distribution.  Thus, individuals with greater degrees of central adiposity develop this syndrome 
more frequently than do those with a peripheral body fat distribution.(Kissebah and Krakower 
1994)  
1.2 BIPOLAR DISORDER 
Patients with bipolar disorder present pleomorphic signs and symptoms that include 
recurring manic, hypomanic and depressive states.  To complicate matters further, individuals 
suffering from bipolar disorder have been particularly afflicted by the rampant increase in 
obesity.  Indeed, these patients have a higher prevalence of obesity (Fagiolini, Frank et al. 2002; 
Fagiolini, Kupfer et al. 2003; McElroy, Kotwal et al. 2004), diabetes (Russell and Johnson 1981; 
Cassidy, Ahearn et al. 1999; Regenold, Thapar et al. 2002), dyslipidemia (Yates and Wallace 
1987; Atmaca, Kuloglu et al. 2002), hypertension (Elmslie, Silverstone et al. 2000), and 
cardiovascular disease (Elmslie, Silverstone et al. 2000; 2001; Lakka, Laaksonen et al. 2002) 
than the general population.  For instance, Elmsie et al (2000) evaluated the prevalence of 
overweight, obesity, and central adiposity in euthymic bipolar patients and reference subjects, 
matched for age and sex.(Elmslie, Silverstone et al. 2000)  Female patients were more often 
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overweight and obese than female reference subjects.  In males, the frequency of being 
overweight was similar in patients and reference subjects although male patients were more 
likely to be obese.  Additionally, this study revealed that patients were more centrally obese than 
the general population and patients treated with antipsychotic drugs were more obese than 
patients not receiving these drugs.  This was later supported by Fagiolini et al (2005) who found 
a 30% prevalence of obesity in bipolar patients taking part in the Pittsburgh Study of 
Maintenance Therapies in Bipolar Disorder.(Fagiolini, Frank et al. 2002) 
Whilst the etiology of obesity and these associated metabolic disorders in patients is 
certainly complex, likely involving a combination of genetic, lifestyle and medication influences, 
it is not known whether these patients are more insulin resistant than would be expected for their 
level of generalized obesity.  Moreover, it is not known whether patients with bipolar disorder 
can be characterized by the sub-clinical correlates of insulin resistance, namely abdominal fat 
accumulation and an impaired capacity for fat oxidation.  
1.2.1 Primary Specific Aims 
Insulin resistance or metabolic syndrome is thought to be a unifying feature of diabetes, 
hypertension, dyslipidemia and cardiovascular disease.  Therefore, identifying and treating 
insulin resistance has immense preventative potential.  The overall goal of this pilot study was to 
determine whether insulin resistance, as well as sub-clinical features of insulin resistance, 
namely patterns of regional fat distribution and lower post-absorptive fat oxidation, distinguishes 
obese and normal weight patients with diagnosed bipolar 1 disorder from obese and normal 
weight controls.   
Two primary specific aims and one secondary aim were addressed (See Table 1). 
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 AIM 1: To compare insulin resistance in women with bipolar 1 disorder to race, age and BMI 
matched controls. 
Hypothesis: Insulin resistance, defined by the homeostatic model assessment 
of insulin resistance (HOMA IR) derived from fasting insulin and glucose, would be 
more severe in obese and normal weight women with bipolar 1 disorder compared to 
obese and normal weight controls.  
AIM 2: To compare visceral and subcutaneous abdominal as well as lower extremity (mid-thigh) 
adipose tissue in women with bipolar 1 disorder to controls.  
Hypothesis:  Obese and normal weight women with bipolar 1 disorder would have more 
visceral and subcutaneous abdominal adipose tissue, but less mid-thigh 
subcutaneous adipose tissue compared to obese and normal weight controls, 
respectively.  
Secondary Aim  To compare resting metabolic rate, rates of post-absorptive fat oxidation, 
energy expenditure and nutritional habits in patients with bipolar 1 disorder and controls.  
Hypothesis: Obese and normal weight women with bipolar 1 disorder would be 
characterized by: a) similar absolute resting metabolic rates and b) lower rates of 
post-absorptive fat oxidation c) lower energy expenditure and d) higher caloric 
intake compared to obese and normal weight controls.  
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Table 1 Primary and Secondary Aims 
 Obese Normal Weight 
 Patients Controls Patients Controls 
↑↑ ↑ ↑ — Insulin Resistance 
↑↑ ↑ ↑ — Visceral Adiposity 
↑↑ ↑ ↑ — Body Composition 
— — — — Resting Metabolic Rate 
— ↑↑ ↑ ↑ Carbohydrate oxidation 
— ↓↓ ↓ ↓ Fat oxidation 
— ↓↓ ↓ ↓ Energy Expenditure 
— ↑↑ ↑ ↑ Caloric Intake 
— Is similar; ↑↑ is highest; ↑is higher; ↓ is lower  
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2.0  SECOND CHAPTER 
2.1 LITERATURE REVIEW 
2.1.1 BACKGROUND 
A key feature of metabolic syndrome is insulin resistance, also a characteristic of 
virtually all individuals with type 2 diabetes.  Obesity and cardiovascular disease is common in 
bipolar disorder, both of which are associated with insulin resistance.  Insulin resistance is also 
associated with distribution of body fat, specifically abdominal visceral fat and fat accumulation 
in skeletal muscle.  Furthermore, reduced capacity to utilize fat has been linked with obesity, 
type 2 diabetes and insulin resistance.  However, it is unclear whether patients with bipolar 
disorder are more insulin resistant than could be expected on the basis of their body weight or 
generalized obesity. 
2.2 BIPOLAR DISORDER 
Bipolar disorder, also known as manic-depressive illness, is a brain psychiatric disorder 
that causes abnormal variations in a person's mood, energy, and ability to function.  It can 
present a recurrent or chronic course and it is characterized by the presence of recurrent 
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depressive episodes, often very severe, and at least one episode of mania, hypomania or mixed 
state.  Each single episode is defined by specific criteria in terms of quality, intensity and 
duration of symptoms (Diagnostic and statistical manual, APA 2000).  Bipolar 1 disorder 
involves at least one or more episodes of mania and depression and has a lifetime prevalence of  
0.4 to 1.6%(Robins 1991; Kessler, McGonagle et al. 1994; Angst 1998)  Bipolar II Disorder 
however, never develops into severe mania but instead the individual experiences milder 
episodes of hypomania that alternate with depression.  Bipolar spectrum includes attenuated 
forms of the disorder, such as cyclothymic disorder, bipolar disorder not otherwise specified 
(NOS) is characterized by episodes of hypomania and depression that do not fulfill either 
duration criteria or number of symptoms.  When factoring in these forms of bipolar disorder, 
lifetime prevalence rates increase to 2-7%.(Angst 1998)  Rapid-cycling occurs when four or 
more episodes of illness occur within a 12-month period and is more common later in the course 
of illness.  
Albeit the prevalence of the more severe form of the disorder is not extremely high, 
especially if compared to other forms of mood disorders such as Major Depressive Disorder, 
bipolar disorder ranks as the sixth cause of disability worldwide (Wyatt and Henter 1995), 
configuring a major economic burden in terms of direct and indirect costs.  The course of illness 
is typically described as episodic, with euthymic inter-episodic periods of variable length; 
nevertheless up to 30% of individuals with bipolar disorder experience residual symptoms and 
psychosocial impairment even during the “recovery” phase, regardless of treatment.(Judd, 
Schettler et al. 2002; Judd and Akiskal 2003)  According to Systematic Treatment Enhancement 
Program for Bipolar Disorder (STEP-BD), approximately 5% of patients who met criteria for 
recovery relapsed each month.   In most cases depression overrides mania and patients tend to 
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spend three times as much time in depression than in mania, regardless of number and polarity of 
episodes.(Judd, Schettler et al. 2002; Judd and Akiskal 2003)  Furthermore, 80% of the patients 
that relapsed in STEP-BD were due to depression.   Bipolar disorder is often under diagnosed or 
misdiagnosed as unipolar depression and it is not infrequent that a lapse of several years occurs 
between the onset of symptoms and the prescription of a mood stabilizer.(Dunner 2003)  
Evidence suggests that the number of previous untreated episodes may negatively affect 
treatment response.(Post 1992) 
Bipolar disorder is commonly treated with mood stabilizers for extended periods of time.  
Due to its effects in controlling mania and preventing recurrence of both episodes, the most 
common mood stabilizer today is lithium.  Anticonvulsant medications such as valproate have 
recently been shown to be useful in treating bipolar episodes although medications may be 
combined for maximum effects.  More recently, the U.S. Food and Drug Administration have 
approved the atypical antipsychotics olanzapine, risperdone, quetiapine, ziprasidone and 
aripiprazole for the treatment of bipolar mania.  In fact, combination therapy with a mood 
stabilizer and an antipsychotic is becoming a common therapy (90%) for patients with 
mania.(Miller, Yatham et al. 2001; Yatham, Kennedy et al. 2003)  Specific risks have been 
associated with atypical antipsychotic treatment such as obesity, diabetes, glucose intolerance,  
thirst and nausea.(Fagiolini, Frank et al. 2002; Regenold, Thapar et al. 2002; McElroy, Kotwal et 
al. 2004) 
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2.3 METABOLIC SYNDROME 
The dramatic increase in obesity in the United States has led to a marked increase in 
metabolic syndrome, a clustering of cardiovascular disease risk factors characterized by visceral 
adiposity, insulin resistance, low HDL cholesterol and systemic inflammatory states.(Ford, Giles 
et al. 2002)  The Adult Treatment Panel III (appears most often used in the literature (Kahn, 
Buse et al. 2005) proposed guidelines for diagnosis highlighting the key features of this 
syndrome.  The definition is based on having 3 of the 5 criteria (central obesity, insulin 
resistance, dyslipidemia, hyperglycemia, and hypertension) though not all persons manifest the 
full syndrome. The diagnosis of metabolic syndrome identifies substantial additional risks for 
type II diabetes and cardiovascular disease.  Therefore, diagnosis of metabolic syndrome may be 
an imperative tool for identification of high-risk patients.  Recently, much attention has been 
focused on the increased rate of metabolic syndrome components among psychiatric patients, 
including glucose intolerance, hyperglycemia, diabetes mellitus, hyperlipidemia, hypertension, 
and weight gain. 
2.3.1 Metabolic Syndrome in Bipolar Disorder 
Risk factors for cardiovascular disease such as obesity and hypertension have been 
examined in patients with bipolar disorder for the past several years, although recently 
researchers have focused their attention on metabolic syndrome.  The prevalence of two 
components of metabolic syndrome, obesity and diabetes, is markedly increasing in patients with 
bipolar disorder.(Fagiolini, Frank et al. 2002; Regenold, Thapar et al. 2002; Kessing, Nilsson et 
al. 2004; McElroy, Kotwal et al. 2004)  Metabolic syndrome is relatively (23.7%) prevalent in 
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the general population (Ford, Giles et al. 2002) though few investigational studies have 
examined metabolic abnormalities in bipolar disorder.  An epidemiological pilot study conducted 
by Basu et al (2004) investigated metabolic syndrome in Schizoaffective Disorder Bipolar 
Subtype.(Basu, Brar et al. 2004)  They recruited patients currently partaking in a double-blind 
study of topiramate or placebo as adjunctive treatment.  Subjects had to receive either lithium 
and/or valproate for at least 2 weeks and could also receive one antipsychotic agent but not an 
antidepressant.  Basu and associates describe a 42% prevalence rate and those with the metabolic 
syndrome were significantly heavier and primarily in the obese range.   
Similarly, Fagiolini et al (2005) examined individuals diagnosed with bipolar disorder 
taking part in the  Bipolar Disorder Center for Pennsylvanians Study (BDCP) which is a multi-
center randomized controlled study involving bipolar I, bipolar II and bipolar not other wise 
specified (NOS) and schizoaffective bipolar subtype.(Fagiolini, Frank et al. 2002)  This study 
included 173 adults from November 2003 to August 2004 and reported that 30% of patients were 
diagnosed with metabolic syndrome in addition to 74% being either obese (45%) or overweight 
(29%). Interestingly, almost half of the participants met criterion for abdominal obesity and 
hypertriglyceridemia whereas approximately 30% met criterion for abnormal HDL cholesterol 
and hypertension. 
2.4 INSULIN RESISTANCE 
Insulin enhances overall energy stores by restricting the release of fuel substrates from 
the tissues into circulation resulting in an increase in cellular uptake of glucose and amino acids.  
In healthy controls, increases in insulin usually occur after meals when exogenous fuels are 
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available.  Insulin also promotes glucose as the preferred oxidative substrate intern sparing 
amino acids and fatty acids for protein and triglyceride synthesis.  The predominant site of 
postprandial glucose disposal is skeletal muscle whereby insulin controls glucose uptake and 
stimulates the oxidation of glucose in addition to glycogen storage.  Overall, insulin orchestrates 
the disposal of carbohydrates after a meal by stimulating glucose uptake and oxidation or storage 
of blood glucose while simultaneously inhibiting endogenous glucose production. When the 
body does not respond well to insulin, this is known as insulin resistance and often develops into 
hyperglycemia.   
Hyperglycemia represents a spectrum of disorders ranging from glucose intolerance to 
type 2 diabetes.  When measured on at least 2 separate occasions, fasting glucose levels between 
110 and 126mg/dL are classified as glucose intolerant and fasting levels ≥ 126mg/dL and 
random glucose levels ≥ 200mg/dL are diagnostic of diabetes.  The World Health Organization 
(WHO) reports that the prevalence of diabetes will be more than double by the year 2025 and the 
prevalence to date has increased to approximately 30%.(Kabinoff, Toalson et al. 2003)   
Insulin resistance is progressed by obesity, inactivity, illnesses, and age and may 
additionally be a prime mechanism in causing dyslipidemia.(Abbott, Lillioja et al. 1987; Garg, 
Helderman et al. 1988; Laakso, Sarlund et al. 1990)  Insulin resistance in respect to glucose and 
fat metabolism has become exceedingly common in obesity especially in upper-body or visceral 
obesity.  Theoretically, this would act to make more lipid fuel available and reduce glucose 
oxidation resulting in excessive adipose lipolysis in addition to increased free fatty acids to the 
liver, although a recent study has shown quite the opposite.  Kelley et al (2000) has shown under 
basal conditions increased, rather than decreased, glucose oxidation as well as impaired fat 
oxidation.  During insulin stimulated conditions these authors report a decreased glucose 
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oxidation in addition to impaired fat oxidation was observed creating a state of “metabolic 
inflexibility.” (Kelley, Goodpaster et al. 1999) 
2.4.1 Insulin Resistance in Bipolar Disorder 
Research has shown that type 2 diabetes is more prevalent in bipolar disorder than the 
general population.(Lilliker 1980; Cassidy, Ahearn et al. 1999; Regenold, Thapar et al. 2002)  
Though insulin resistance has not been examined directly in bipolar disorder, one of the primary 
defects of type 2 diabetes is insulin resistance, one can hypothesize that individuals diagnosed 
with bipolar disorder also have an increased prevalence of insulin resistance. 
2.5 OBESITY 
National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) estimated that 
obesity is becoming a worldwide emergency with over 280,000 deaths directly attributed to 
obesity related morbidity.  Major problems linked with obesity include hypertension, 
cardiovascular disease, dyslipidemia, diabetes mellitus, gallbladder disease, osteoarthritis, 
gallstones, musculoskeletal problems, and some cancers.  Furthermore, it is estimated that 
approximately $68 billion per year is spent on economic costs of illnesses associated with 
obesity.(Wolf 1998)   
Obesity is one of the central components of metabolic syndrome (Matsuzawa, Funahashi 
et al. 1999; Montague and O'Rahilly 2000) but the mechanistic role of obesity has not been fully 
elucidated.  Adipocytes produce a variety of active molecules such as adipocytokines, including 
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plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-α (TNF- α), resistin, leptin and 
adiponectin.  Any irregularities in these molecules have been associated with the 
pathophysiology of obesity related metabolic syndrome.  An accumulation of fat has been 
reported to increase PAI-1 and TNF- α, contributing to the development of insulin resistance.  In 
contrast, decreases in adiponectin have been shown to be causative of insulin resistance; 
however, the exact mechanism by which fat accumulation contributes to irregularities in 
molecules is unknown.  Furukawa et al (2004) investigated whether oxidative stress in 
accumulated fat may in part be the underlying cause of abnormalities in adipocytokines and 
therefore the development of metabolic syndrome.(Furukawa, Fujita et al. 2004)  They report 
that fat accumulation is correlated with oxidative stress in humans and mice.  Specifically, 
elevated levels of fatty acids increased oxidative stress in turn causing dysregulation of 
adipocytokines including adiponectin and PAI-1.  Furthermore, Furukawa and colleagues 
reported that treatment with NADPH attenuated dysregulation of adipocytokines, improved 
diabetes and hyperlipidemia. 
2.5.1 Obesity in Bipolar Disorder  
Individuals diagnosed with bipolar disorder have an increased prevalence of obesity 
(Elmslie, Silverstone et al. 2000; Fagiolini, Frank et al. 2002; McElroy, Frye et al. 2002; Keck 
and McElroy 2003) most of which appears to be abdominally stored.(Elmslie, Silverstone et al. 
2000; McElroy, Kotwal et al. 2004) (Fagiolini, Frank et al. 2002)  Treatment of obesity has 
become important to physicians today since obesity has been correlated with a poorer outcome 
(Fagiolini, Kupfer et al. 2003) and discontinuation of therapy.(Tardieu, Micallef et al. 2003)  
Furthermore, the number of previous depressive episodes contributes to obesity (Fagiolini, Frank 
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et al. 2002) and bipolar patients seeking to lose weight have higher rates of depression.(McElroy, 
Kotwal et al. 2004) 
Since most patients spend their time suffering from depressive symptoms or depressive 
episodes, bipolar disorder itself may be an underlying risk of obesity and other related morbidity 
and mortality.(Judd, Schettler et al. 2002; Judd and Akiskal 2003; Nolen, Luckenbaugh et al. 
2004)  Risk factors such as co-morbid binge-eating disorder, number of depressive episodes, and 
treatment with medications associated with weight gain, excessive carbohydrate consumption 
and low rates of exercise have also been shown to increase the risk of obesity in these 
patients.(Fagiolini, Kupfer et al. 2003), (Kruger, Shugar et al. 1996), (Graham, Perkins et al. 2005), (Deshmukh and Franco 
2003) 
 
2.5.2 Causes of Obesity in Bipolar Disorder  
Obesity appears to be a proxy for medical burden in patients with mood disorders and 
may be multifaceted, consisting of environmental, genetic and medication factors.  They may be 
independent conditions with completely separate patho-physiological pathways or they may co-
occur by causal association, though the exact mechanism is unknown. 
Bipolar disorder itself: 1) Some peculiar features in the biology of mood disorders may 
also play a role in the development of a high BMI.  Hyperactivity of Hypothalamic Pituitary 
Adrenal (HPA) axis is one of the most consistent biological findings in mood 
disorders,(Holsboer and Barden 1996) and it may persist after clinical remission of 
symptoms.(Rybakowski and Twardowska 1999)  Furthermore, there is also evidence that the 
HPA axis may precede mood episode,(Heuser, Schweiger et al. 1996) and is a risk factor for 
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relapse when there is no normalization after treatment.(Zobel, Yassouridis et al. 1999)  Animal 
studies have consistently shown interaction between HPA axis and the serotonin system, and 
HPA axis dysregulation seems to be related to serotonergic system abnormalities.(Porter, 
Gallagher et al. 2004)  Nevertheless, long before the extensive use of psychotropic medications, 
Kretschmer (1921) described a somatic typology (pyknic body type) that was characterized by an 
abdominal fat pattern, and that was associated with “cycloid temperament” and predisposition to 
manic-depressive psychosis. 
2) More recent prospective studies have established that depression is a risk factor for 
weight gain and obesity and child or adolescent depression predicts greater BMI in 
adulthood.(Pine, Cohen et al. 1997)  In cross-sectional analyses, depression, but not mania, 
seems to be a correlate for obesity in bipolar disorder.(Fagiolini, Kupfer et al. 2003)  Bipolar 
depression often portrays atypical symptoms (Akiskal, Walker et al. 1983; Mitchell, Wilhelm et 
al. 2001) that are associated with hyperfagia, binge eating and weight gain.(Angst, Gamma et al. 
2002)  Binge eating is a common eating pattern in obese subjects.(Bulik, Sullivan et al. 2002; 
Yanovski 2003) and it is frequently reported by patients with bipolar disorder.(Kruger, Shugar et 
al. 1996)  McElroy and colleagues reported that 13.5% of obese patients with bipolar disorder 
and 50% of extremely obese patients with bipolar disorder had current or lifetime history of 
binge eating, compared to 4.9% of normal weight bipolar subjects,(McElroy, Frye et al. 2002) 
suggesting that the engagement in abnormal eating behavior may be a pathway to obesity for 
patients with bipolar disorder.  On the other hand, high prevalence of mood disorder is reported 
for treatment-seeking obese binge eaters (Bulik, Sullivan et al. 2002; Yanovski 2003) and binge 
eating is associated with increased medical comorbidity independent from BMI.(Bulik, Sullivan 
et al. 2002)  
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Medication Induced Obesity: The most relevant question regarding obesity and bipolar 
disorder is whether obesity is increased independent of medication.  Additionally, if medication 
does induce obesity, to what extent do you see an increased rate of medication induced obesity?  
This current project is not intended to address the relationship between medications and obesity 
although it is intended to serve as a segway into future projects to examine this issue more 
closely.  1) One hypothesis is that the current medications used to treat bipolar disorder increase 
energy intake.(Elmslie, Mann et al. 2001)  Current evidence suggests that increased energy 
intake seems to begin with afferent signals (i.e. leptin, ghrelin etc) alerting the hypothalamus to 
the state of the body’s environment.  This mechanism may either stimulate appetite (food intake) 
or decrease appetite to maintain adipose mass.(Kennedy 1953; Kennedy 1966)  Although neither 
leptin nor ghrelin have been shown to be a causal factor in the development of obesity in the 
healthy population (Baptista and Beaulieu 2002) they have not been examined in patients with 
bipolar disorder. 2) Most medications currently used as maintenance treatment can cause weight 
gain and some are thought to directly affect glucose and lipid metabolism.(Bergman and Ader 
2005; Newcomer 2005)  Atypical antipsychotics, common today in treating bipolar disorder, 
have been shown to promote serotonin antagonism at the 5-HT2c receptors and dopamine 
antagonism eliciting increased caloric intake.  Furthermore, metabolic ailment with some 
antipsychotics may contribute in unwanted energy storage promoted by a reduced oxidation of 
fat.(Graham, Perkins et al. 2005)   
Common Biological Diathesis:  1) Both obesity (Haslam and James 2005) and bipolar 
disorder (Mathews and Reus 2003; Tsuang, Taylor et al. 2004; Mansour, Monk et al. 2005) seem 
to have a complex genetic pattern, with multiple genetic variants.  One hypothesis is that there 
may be a common genetic vulnerability for obesity and bipolar disorder that include 
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serotonergic, dopaminergic and noradrenergic systems, involved either in mood regulation or in 
food intake. For example, two variants with functional impact in the promoter region of the 
Serotonin (5HT) Transporter (5HTT) have been identified.  Briefly, these two variants represent 
a short allele (S) and a long allele (L).  The presence of the S allele has been associated with 
lower selective serotonin reuptake inhibitor (SSRI) response in depression(Pollock, Ferrell et al. 
2000) and Bulimia Nervosa,(Monteleone, Santonastaso et al. 2005) homozigousity SS has been 
associated with bipolar disorder and recurrent depression.(Collier, Arranz et al. 1996)  This data 
suggest that there may be an overlap in the pathogenesis of affective disorders and disordered 
eating (possibly via affect instability and impulsivity) and that the functional correlate of this 
genetic marker may be dimensional, rather than sequential.  
2) Mesolimbic dopaminergic pathways may also be involved in the regulation of affect 
and eating.(Balleine 2005)  A variant of the dopamine receptor gene DRD4 has been associated 
with binge eating and higher lifetime BMI in women with Seasonal Affective Disorder 
(SAD).(Levitan, Masellis et al. 2004)  Furthermore, functional neuroimaging studies show a 
substantial overlap between neural circuits involved in affect regulation and neural circuits 
involved in food-related stimuli.(Price 1999; Killgore, Young et al. 2003)  There is a speculation 
that a predisposition to obesity may involve areas of the brain that control complex aspects of 
eating behavior including anticipation and reward, chemosensory perception, and autonomic 
control of digestion, enteroception and learning memory (del Parigi A; Chen K, 2004).  
2.5.3 Central Obesity 
Central obesity is associated with hypercortisolemia in the general population,(Bjorntorp 
and Rosmond 2000) and the functional correlates of cortisol levels in patients with mood 
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disorders has been poorly investigated.  Hypercortisolemia has been proposed to be the major 
cause of visceral fat deposition in patients with mood disorder, but there is only one study 
addressing this issue.  Weber-Hamann et al. compared 22 postmenopausal depressed women to 
23 matched controls.  The author’s report a larger mass of visceral fat in hypercortisolemic 
depressed patients (113.0 ± 41.6cm2) compared to normocortisolemic depressed patients (74.5 ± 
55.5cm2).  However, no differences were observed in visceral fat stores once patients were 
compared to controls (Lumbar 1= 113.0 ± 41.6 vs. 94.3 ± 53.2cm2  and Lumbar 4 = 117.5 ± 46.3 
vs. 118.1 ± 57.2 cm2).(Weber-Hamann, Hentschel et al. 2002) 
Regional obesity has also shown to be associated with insulin resistance.  Studies 
examining visceral adiposity have given us tremendous insight into the link between insulin 
resistance and obesity.  Specifically abdominal adiposity has been strongly associated with 
insulin resistance of skeletal muscle,(Despres 1993) dyslipidemia (Tchernof, Lamarche et al. 
1996) and glucose intolerance.(Bjorntorp 1991; Despres 1993)  Carey et al (1996) examined the 
relationship between abdominal fat and insulin resistance through dual-energy x-ray 
absorptiometry (DEXA) and insulin sensitivity via euglycemic-hyperinsulinemic clamp in 
healthy women.(Carey, Jenkins et al. 1996)  They found a strong negative correlation (r = -0.89, 
P = < 0.0001) between central abdominal fat defined as intra-abdominal plus abdominal 
subcutaneous fat and whole-body insulin sensitivity.  In a more specific analyses, Brochu et al 
(2000) examined independent associations of regional adiposity and total fat mass with glucose 
disposal in obese older women.(Brochu, Starling et al. 2000)  Upon stabilizing metabolic 
assessments and dietary intake for three days in all subjects, visceral adipose tissue showed a 
similar (r = -0.40, P = < 0.01) association to total glucose disposal expressed as per kg normal 
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weight body mass as the previous study even upon adjustment of total fat mass (r = - 0.45, P= < 
0.005).   
2.5.4 Central Obesity in Bipolar Disorder 
Increased rates of abdominal adiposity have been reported in bipolar disorder.(Elmslie, 
Silverstone et al. 2000; Fagiolini, Frank et al. 2002; McElroy, Kotwal et al. 2004)  Confounding 
variables such as psychological disorder, duration of illness and treatment modalities have made 
the primary mechanism difficult to interpret in this population.  Cross sectional investigations 
reporting observed abdominal obesity have used waist circumference as the primary means of 
assessment. Although waist circumference is a surrogate of total abdominal adipose tissue, waist 
circumference does not distinguish visceral from subcutaneous abdominal adipose tissue.  
Weber-Hamann et al. (2002) compared 22 postmenopausal depressed women to 23 matched 
controls (Weber-Hamann, Hentschel et al. 2002) with computed tomography.  A single slice was 
performed at the level of lumbar vertebra 1 and lumbar vertebra 4.  As stated previously, no 
differences were observed in visceral fat stores once patients were compared to controls in either 
lumbar region (L1= 113.0 ± 41.6 vs. 94.3 ± 53.2cm2  and L4 = 117.5 ± 46.3 vs. 118.1 ± 57.2 
cm2).   
2.6 SKELETAL MUSCLE FATTY ACID METABOLISM 
High proportions of upper-body or abdominal fat has been recognized to be an important 
component of insulin resistance in obesity and type 2 diabetes; although, there is also evidence 
 19 
suggesting that thigh adipose tissue is also an important link in insulin resistance.  The amount of 
triglyceride in skeletal muscle has been associated with insulin resistance (Pan, Lillioja et al. 
1997; Kelley, Goodpaster et al. 1999; Goodpaster and Kelley 2002) and has been shown to be 
increased in obesity.(Kelley, Goodpaster et al. 1999; Goodpaster and Wolf 2004)  Several studies 
have previously shown that increased skeletal muscle lipid content is associated with the severity 
of insulin resistance,(Goodpaster, Thaete et al. 1997; Pan, Lillioja et al. 1997) although others 
disagree.(Carey, Jenkins et al. 1996) 
 Carey et al (1996) showed that thigh fat content measured by DEXA was not associated 
with insulin resistance.(Carey, Jenkins et al. 1996)  Philips et al (1996) examined thigh 
intramuscular triglycerides and its association with insulin action measured by whole-body 
insulin sensitivity and by the ability of insulin to activate glycogen synthase in normal glucose 
tolerant women.(Phillips, Caddy et al. 1996)  They reported that muscle triglyceride content 
measured biochemically correlated with glycogen synthase activation but not with glucose 
tolerance, insulin resistance or central obesity.  Authors believe this may have occurred because 
the triglyceride content of the biopsy reflects the amount of interstitial and intracellular fat which 
supports that not all adipose tissue accumulated in skeletal muscle is subcutaneous.   
Adipose tissue can also accumulate beneath the fascia lata and within muscle itself 
(Nordal, Dietrichson et al. 1988; Liu, Chino et al. 1993) suggesting the distribution within the 
thigh may be a component of regional fat deposition that is indeed associated with insulin 
resistance.  For example, Goodpaster et al (2000) examined compartmentalization of thigh 
adipose tissue, assessed by computed tomography, and its association with insulin resistance in 
lean glucose tolerant, obese glucose tolerant and obese type 2 diabetic subjects.(Goodpaster, 
Thaete et al. 2000)  They observed that obese diabetic and obese glucose tolerant subjects had 
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lower insulin sensitivity than lean glucose tolerant subjects.  Furthermore, they report that 8% of 
adipose tissue in the thigh was located beneath the fascia and correlated (r = -0.36, P <0.01) with 
insulin sensitivity.  Additionally, intramuscular adipose tissue comprised only 3% of thigh 
adipose tissue but showed an even stronger correlate (r = -0.45, P < 0.01) of insulin resistance.  
Goodpaster and associates also support previous findings (Carey, Jenkins et al. 1996) that 
subcutaneous adipose tissue is not a predictor of insulin resistance.  
2.6.1 Mechanisms 
Several mechanisms may be involved for the impairment in skeletal muscle by either 
uptake or oxidation of plasma fatty acids.  Blaak et al (2000) showed a lower rate of appearance 
of free fatty acids (FFA) in type 2 diabetic subjects both under basal and exercise conditions 
suggestive of an impairment of disposal and oxidation of fatty acids.(Blaak, van Aggel-Leijssen 
et al. 2000)  There have also been indications that muscle lipolysis may be increased in type 2 
diabetic subjects.  An increase in muscle lipolysis may overflow the muscle thereby decreasing 
the blood-tissue concentration gradient, one of the primary determinants of plasma fatty acid 
uptake and oxidation.(Van der Vusse 1996)  Lastly, skeletal muscle is dependent on oxidative 
phosphorylation for energy production.  Both obesity and type 2 diabetes involves dysregulation 
of both the oxidation of fat and carbohydrates as fuel.(Kelley, Goodpaster et al. 1999) Therefore, 
perturbations in mitochondrial function has also been implicated (Kelley, He et al. 2002) 
specifically related to carnitine palmitoyle transferase (Simoneau, Veerkamp et al. 1999) and 
lowered pattern of various fatty acid-binding proteins.(Luiken, Schaap et al. 1999)    
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2.7 MEDICATIONS IN BIPOLAR DISORDER 
Physicians have been treating symptoms of psychiatric illness for decades with 
conventional antipsychotics, tricyclic antidepressants, benzodiazepines, selective serotonin 
reuptake inhibitors, cholinesterase inhibitors and most recently, atypical antipsychotics.  As 
stated previously, this study is not examining medication affects on obesity or insulin resistance.  
This section is intended to illustrate what research has shown about specific types of medications 
used to treat bipolar disorder.  This section is also revealing why the current study has chosen to 
exclude patients on certain medications such as olanzapine and clozapine.  
2.7.1 Antidepressants 
 Weight gain may be caused by the pharmacological effect of antidepressants or an effect 
of recovery from depression.  Antidepressant medications fall into varying classes such as 
tricyclic antidepressants, irreversible monoamine oxidase inhibitors and selective serotonin 
reuptake inhibitors (SSRI’s).    
2.7.2 Monoamine oxidase inhibitors (MAOI)  
MAOIs are effective in treating depression and anxiety and can bind to receptors either 
irreversibly or reversibly.  Reversible MAOIs are less likely to cause weight gain but are 
currently not available in the United States.  Irreversible MAOIs on the other hand have been 
shown to cause weight gain with the most common being phenelzine.(Fava 2000)  
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2.7.3 Tricyclic Antidepressants  
Tricyclic Antidepressants are well known for their adverse effects on weight gain (Fava 
2000) and possibly as a result of excessive appetite.  Fernstrom and Kupfer (1988) reported that 
treatment with three tricyclic compounds promoted weight gain with amitriptyline adding greater 
weight gain than nortriptyline and desipramine.(Fernstrom and Kupfer 1988)  Frank et al (1990) 
reported roughly 13% to 15% of patients treated with imipramine gained 10 or more pounds by 
week 16 or 33.(Frank, Kupfer et al. 1990)  Many mechanisms have been hypothesized including 
blockade of histamine H1 and serotonin 2C receptors, carbohydrate craving, changes in body fat 
stores and recovering from clinical depression.(Deshmukh and Franco 2003)  
2.7.4 Selective Serotonin Reuptake Inhibitors (SSRI)  
SSRIs elicit little to no weight gain when used for 6 months or less although literature is 
mixed when treatment surpasses 1 year or longer. Some short term studies have revealed a 
weight loss of 0.3 to 0.8kg with fluoxetine and sertraline (Croft, Settle et al. 1999; Michelson, 
Amsterdam et al. 1999).  In contrast, Michelson et al (1999) examined changes in weight during 
a 1-year trial of fluoxetine and found no significant weight gain with fluoxetine.(Michelson, 
Amsterdam et al. 1999)  Although, a 12-month placebo-controlled study revealed 4.7% of 541 
patients treated with citalopram experienced weight gain of greater than 5kg.(Wade A 1999) 
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2.7.5 Atypical Antipsychotics 
To date, there are 6 atypical antipsychotics marketed in the United States: clozapine, 
risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole.  Atypical antipsychotics have 
been shown to produce substantially less extrapyramidal symptoms and prolactin increase 
compared to conventional antipsychotics, although impaired glucose homeostasis has recently 
been attributed to some atypical antipsychotic use, specifically clozapine and 
olanzapine.(Wirshing, Wirshing et al. 1999)  
Antipsychotic induced obesity is difficult to assess and previous research to our 
knowledge has focused on neurotransmission and hormones as possible causes.  In patients with 
bipolar disorder, standard risk factors may not provide a link between type II diabetes and some 
atypical antipsychotics.  Complicating this relationship is the observation that patients with 
bipolar disorder have higher rates of diabetes than the general population.(Lilliker 1980; Cassidy, 
Ahearn et al. 1999; Regenold, Thapar et al. 2002)  Little is known about the relationship between 
atypical antipsychotic medication and bipolar disorder since it has not been examined.  With the 
recent use of antipsychotic medications used to treat bipolar disorder, this area needs to be 
further investigated.   
In summary, patients with bipolar disorder have higher prevalence of type 2 diabetes.  A 
primary factor in diabetes is insulin resistance which has been an understudied topic in this 
disorder.  There may as well be an association between insulin resistance and bipolar disorder 
although it is unknown if their insulin resistance is irrespective of their generalized obesity or if 
they encompass sub-clinical features of insulin resistance, (i.e. reduced capacity to utilize fat.)  
Distinguishing insulin resistance and its sub-clinical correlates in these patients may help to 
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identify the appropriate targets for outcomes that could be examined further in intervention trials 
designed to prevent or treat their insulin resistance and type 2 diabetes.  Lastly, methodological 
techniques (e.g. Resting Metabolic Rate, fat oxidation and CT scanning) employed in this current 
protocol have not been examined in bipolar patients and will provide novel information 
regarding insulin resistance in patients treated for bipolar disorder. 
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3.0 CHAPTER 3 
3.1 METHODS 
3.1.1 Subjects 
The Pittsburgh Institutional Review Committee approved the study, and all subjects 
provided written, informed consent (APPENDIX A) at the time of their initial visit to the 
General Clinical Research Center (GCRC).  Participants were excluded if taking chronic 
medications known to adversely affect glucose homeostasis (thiazide diuretics, oral 
glucocorticoids, nicotinic acid, and oral steroids) or had a history of myocardial infarction, 
peripheral vascular disease, neuromuscular disease, proteinuria, liver disease, current alcohol or 
drug abuse, or current malignancy (Table 2).  Women who were pregnant or lactating or who lost 
or gained >5kg in the past month were also excluded.  Eighteen bipolar 1 patients and 17 
controls participated in this study.  
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 Table 2 Inclusion/Exclusion Criteria 
INCLUSION CRITERIA EXCLUSION CRITERIA 
18-60 years of age Diabetic I or II 
Bipolar 1 currently euthymic and race,  age 
and BMI matched controls 
Weight gain or loss of >5kg in past 1 
month 
Women Inability or unwillingness to comply with 
the protocol 
Non-diabetic Current alcohol or substance abuse 
Non-Pregnant ALT >80, AST>80, Alk Phos >240 
Stable weight for 1 month defined as no 
weight gain or loss of ≥5kg in past 1 month 
Proteinuria (defined as >1 + on routine 
dipstick), hypothyroidism (sTSH>8) 
Bipolar patients currently taking  ≤3 
medications 
Claustrophobia 
No lifetime history of olanzapine or 
clozapine treatment. 
Treatment with thiazide diuretics, oral 
glucocorticoids, nicotinic acid or Females 
currently taking oral contraceptives or 
hormone replacement therapy (HRT) < 
3months. 
3.1.2   Bipolar Patients 
The study populations was selected from participants in the Bipolar Disorders Center for 
Pennsylvanians (BDCP) and met DSM-IV criteria for bipolar 1 disorder, were euthymic and 
were treated with ≤ 3 medications.  Medications classified to treat the disorder are located in 
Table 3.  Any lifetime history of Olanzapine and/or Clozapine treatment were excluded due to 
their effect on glucose homeostasis.(Wirshing, Wirshing et al. 1999)  Patient’s history of 
medication was tracked through BDCP medical records and self report. 
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 Table 3 Medications Included and Excluded 
Medications Included Medications Excluded 
Depakote (valproate) Zyprexa (Olanzapine) 
Topamax (topiramate) Clozaril (Clozapine) 
Geodon (Ziprasidone) Nicotinic acid 
Lamictal (Lamotrigine) Thiazide Diuretic 
Neurontin (Gabapentin) Oral Glucocorticoids 
Seroquel  (Quetiapine) Oral contraceptives < 3 Months 
Risperdone (Risperidone) Hormone Replacement Therapy < 3 
Abilify (Aripiprazole)  
Lithium  
Carbamazepine (Tegretol)  
Haloperidol (Haldol)  
Sertraline (Zoloft)  
Lorazepam (Ativan)  
3.1.3 Controls:  
Matched controls were defined as participants who had no lifetime history of mood, 
anxiety, psychotic, eating, sleeping, and somatoform disorders and have never been treated with 
any neuroleptic medication.  Control subjects were matched to bipolar 1 patients by race, age, 
and BMI. 
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 3.2 EXPERIMENTAL DESIGN AND METHODS 
 
3.2.1 Screening Procedures 
All subjects were admitted to the GCRC after an overnight fast and completed informed 
consent, structured clinical interview (SCID) demographic questionnaire (APPENDIX B), food 
frequency questionnaire (FFQ) and a blood draw to measure CBC, electrolytes, liver function, 
thyroid function, blood glucose, insulin levels and blood fat levels (cholesterol, HDL, LDL, 
triglycerides) Table 4.  As addressed in Aim 1 of this pilot study, insulin resistance were 
compared in women with bipolar 1 disorder to controls.  Insulin resistance was defined by the 
homeostatic model assessment of insulin resistance (HOMA IR [glucose X 
insulin]/22.5).(Mathews 1985)  The demographic questionnaire collected information such as 
age, height, weight, socioeconomic status, education level, working status and psychiatric 
history.  The food frequency questionnaire (FFQ) estimated the usual consumption frequency of 
79 main food items over the preceding 12 months (Block, Hartman et al. 1986).  Moreover, the 
FFQ comprised of questions regarding nutritional habits, preparation methods, and additions.  
Photographs of dishes were used to estimate habitual portion sizes.  Food consumption data was 
converted into macronutrients and micronutrients by use of an updated version of the 
computerized Dutch food composition table 1996.  Overall, the questionnaire enabled an 
estimation of the average daily consumption of 178 food items. 
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Upon completion of visit 1, all participants completed the following procedures to 
determine differences in energy expenditure, body composition and resting metabolism as stated 
in Aim 2 and the Secondary Aim (Visit 2).  
 
 
Table 4  Protocol Visits 
Visit 1 5-day Energy  Visit 2 
 (Screening) Expenditure  (Experimental) 
Resting Metabolic Rate 
3.2.2 Physical Activity Measurement (Following Visit 1): 
Upon the screening visit, subjects were given a Body Media Armband for approximately 
five days to measure total energy expenditure (kcal/24h), active energy expenditure (kcals 
derived from metabolic equivalent) and sleep duration. A unit of metabolic equivalent, or MET, 
is defined as the number of calories consumed per minute in an activity relative to the basal 
metabolic rate.  One MET is the caloric consumption while at complete rest whereas BodyMedia 
 Questionnaires- 
 BodyMedia 
Armband 
 Fat oxidation/  Structured Clinical Interview 
Diagnostic (SCID)  Carbohydrate oxidation 
  Demographic 
 Food Frequency 
Questionnaire (FFQ)  Dual X-ray Absorptiometry 
 Fat Free Mass 
 Fat Mass 
Blood Draw  Computed Tomography 
 Blood Lipid Profile  Scans of abdomen 
 Glucose/Insulin  Scan of thigh 
Total Time:  Total Time: 
1.5 Hours 2.5 Hours 
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defines total energy expenditure as < 2.5 METs.  The armband is a multi-sensor device 
consisting of a body-contoured monitor with adjustable straps to keep the sensor in contact with 
the arm during a variety of activities and conditions.  The armband provides an assessment of 
overall physical activity and has recently shown to be a valid determinant of free-living energy 
expenditure.(Jakicic, Marcus et al. 2004)  Subjects were asked to perform their visit 1 on 
Wednesday and were given the armband at that time.  Subjects wore the armband on the upper 
right arm and returned back to the GCRC to complete visit 2 on Monday.  At visit 2, expenditure 
measurements were collected on both weekdays and weekends.  Data retrieved from the 
Armband was analyzed via customized algorithms to determine derived energy expenditure, 
level of activity and sleep state.  
Individuals returned following the 5 day energy expenditure measurement to complete 
metabolic measurements (description to follow) after 12 hour overnight fast. Fasting measurements 
were essential due to confounding influences of preceding food intake on substrate metabolism.  
3.2.3 Visit 2  
The Second Aim of the study set out to compare visceral and subcutaneous abdominal, as 
well as lower extremity (mid-thigh), adipose tissue in women with bipolar 1 disorder to controls.  
Dual Energy X-Ray Absorptiometry (DEXA; model DPX-L; Lunar Corp., Madison, WI) scans 
performed at the Obesity Nutrition Research Center (ONRC) were used to assess body composition 
(i.e., total body fat and fat free mass as covariates).  Computerized Tomography (CT) scans were 
performed at Presbyterian University Hospital Radiology Department in collaboration with Dr. F. 
Leland Thaete.  CT was used to measure abdominal visceral and intermuscular adipose tissue as 
primary endpoint (independent) variables as previously described (Goodpaster, Thaete et al. 1997).  
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Briefly, a cross-sectional area of abdominal fat was assessed with a single CT scan centered upon 
the L4-L5 vertebral disk space.  A single slice between the anterior superior iliac crest and the 
inferior margin of the patella divided by ½ was used for the intermuscular adipose assessment.  CT 
scans provided data on visceral abdominal adipose tissue area, subcutaneous abdominal adipose 
tissue area, total abdominal adipose tissue area, thigh muscle area, thigh subcutaneous adipose 
tissue area and thigh intermuscular adipose tissue area. 
The Secondary Aim quantified resting metabolic rate and substrate (fat and carbohydrate) 
oxidation using systemic indirect calorimetry with an open canopy system (DeltaTrac, Anaheim, 
CA).  The evening prior to testing, subjects received a telephone call from the study coordinator 
to remind the patient not to eat or drink anything after 12A.M. and to minimize movement as 
much as they could the morning of testing.  Directions to minimize movement involved taking 
the elevator instead of the stairs and having another person drive them to the visit.  The subject 
arrived at the GCRC after an over night fast where a clear plastic canopy was placed over their 
face and neck to collect the amount of oxygen their body used.  This test was performed for 35 
minutes in order to estimate carbohydrate and fat oxidation from expired O  and CO2 2 
measurements.  The average rates of resting fat and carbohydrate oxidation were measured 
during the last 30 minutes of the measurement period.  During measurements, subjects were told 
to refrain from talking, fidgeting and sudden movements.  The equations C = [4.55 (Vco2 – 3.21) 
– (Vo2 – 2.87)] (where C is grams of carbohydrates) and F = [1.67 x (Vo2 – 1.67) – (Vco2 – 
1.92)] (where F are grams of fat per minute) developed by Frayn KN, (1983) were used to 
determine rates of resting fat and carbohydrate oxidation in g· min-1 (Frayn 1983). 
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3.3 DATA ANALYSES 
Statistical analyses were performed using SPSS 13.0 (Chicago, IL) with statistical 
significance defined as p ≤ 0.05.  All data are expressed as mean SEM.  Initially, data was 
analyzed to provide information on subject characteristics, insulin resistance, body composition, 
fat oxidation, energy expenditure and nutritional habits.  Normal distribution was analyzed prior 
to conducting additional analyses.  Differences in Primary Aims and Secondary Aims were 
conducted using One-Way Analyses of Variance (ANOVA).  Pearson correlation coefficient was 
used to determine the relationship between insulin resistance and percent body fat and visceral 
fat.   
Our sample size estimates were based on a previous study (Goodpaster, Thaete et al. 
1997) in which fasting insulin levels (Primary Aim) were significantly different (P<0.01) in 
obese (15.8 ± 10.1 mU/ml) and normal weight (6.5 ± 3.3 mU/ml) subjects.  We needed 15 
subjects in each of the four groups in order to have 80% power to determine a similar effect size 
in patients compared to controls (both obese and normal weight). 
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4.0 CHAPTER 4 
4.1 RESULTS 
4.1.1 Subjects 
Insulin resistance and sub clinical features of insulin resistance were compared in 18 
patients with bipolar 1 disorder and 17 controls matched for race, age and BMI.  Twelve patients 
and 12 controls were obese by BMI criteria (BMI 35.2 ± 1.1 vs. 34.0 ± 1.4kg/m2) and 6 patients 
and 5 controls were normal weight (BMI 22.8 ± 0.7 vs. 23.2 ± 0.9kg/m2).  All subjects were 
women. 
Patients were treated with ≤ 3 medications during the study duration.  Ten subjects were 
treated with antipsychotic medications (Abilify, Geodon, Haldol or Seroquel), 6 with 
antidepressants (Ativan, Wellbutrin, Effexor, Prozac, Lexopro and Zoloft) 7 with mood 
stabilizers (Lithium, Depakote, and Tegretol), 2 with anti-anxiety (trilafon), 6 with anti-
convulsants (Neurontin, Topomax and Lamictol), 1 on an SSRI (Celexa), 1 on hypertensive 
medication (Licinopril) and 1 on hypothyroid medication (Synthroid).  Patients were not treated 
with any medication known to affect glucose homeostasis.  Matched controls were not treated 
with any psychotropic medication nor had any previous history of mental ailment.  There were 2 
control subjects (1 obese and 1 lean) treated with hypertensive agent and 1 on anti-Parkinson 
agent.  By design, age, weight, race and BMI were not different between groups,  
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 Table 5 Subject Characteristics 
Obese Normal Weight  
 Patients Controls P Value Patients Controls P Value
Age 42 ± 2.0 43 ± 2.5 0.65 40.8 ± 4.1 38.2 ± 4.4 0.67 
Weight (kg) 97.9 ± 4.2 90.1 ± 5.0 0.24 66.3 ± 2.1 62.3 ± 3.8 0.35 
BMI(kg/m2) 35.2 ± 1.1 34.0 ± 1.4 0.53 22.8 ± 0.7 23.2 ± 0.9 0.75 
Race 1.00 ± 0.0 1.08 ± 0.1 0.33 1.33 ± 0.21 1.00 ± 0.00 0.19 
Values represent mean ± SEM, as expected, there were no differences observed in age, weight, BMI or Race. 
4.1.2 Insulin Resistance 
In both obese and normal weight women, fasting glucose and insulin levels were similar 
in patients with bipolar disorder compared to controls (Table 6).  Insulin resistance, defined by 
the homeostatic model assessment of insulin resistance (HOMA IR), was not different between 
obese patients and controls (56.8 ± 17.2 vs. 51.0 ± 10.3; P=0.84; Figure 1), normal weight 
patients and controls (30.5 ± 6.3 vs. 27.0 ± 5.7 P=0.78; Figure 1) or when combining obese and 
normal weight patients to obese and normal weight controls (45.2 ± 11.1 vs. 47.5 ± 9.5 P=0.80; 
Figure 2.  These results are in contrast to our primary hypothesis that patients would be more 
insulin resistant than non-patient controls.  There was a trend for both groups of obese women, 
both patients and controls, to be more insulin resistant than normal weight women (54.3 ± 10.0 
vs. 28.9 ± 7.2, P=0.10).   
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Figure 1 HOMA in Obese and Normal Weight Women 
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Figure 2 HOMA in Patients and Controls 
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4.1.3 Metabolic Characteristics 
Total serum cholesterol, LDL, HDL or triglyceride levels were not different between obese 
patients and controls or normal weight patients and controls, Table 6. Upon combining the 
groups, LDL was significantly higher in controls compared to patients (124.9 ± 6.8 vs. 102.7 ± 
7.7mg/dL, P=0.04; Table 7) compared to patients and there was a trend for controls to have higher 
cholesterol (207.7 ± 11.7 vs. 182.7 ± 8.0mg/dL, P= 0.08) although no other differences were observed, 
Table 7.  One patient had a missing LDL and VLDL value due to elevated plasma triglycerides, 
preventing LDL and VLDL calculation.  Blood pressure, a parameter of the metabolic syndrome, 
was significantly higher in obese patients compared to controls (P=0.01) although normal weight 
controls had higher diastolic blood pressure (P=0.03), but no difference in systolic, compared to 
normal weight patients.  Controls together (obese and normal weight) had higher diastolic blood 
pressure compared to patients (P = 0.04).  
 
 
 
 
 
 
 
 
 
 
 38 
 
Table 6 Metabolic Characteristics of Obese and Normal Weight Women 
Obese Normal Weight  
 Patients Controls  Patients  Controls  
PValue PValue (n = 12) (n = 12) (n = 6) (n = 5) 
Cholesterol, mg/dL 187 ± 10.3 207.58 ± 15.0 0.28 180.5±17.4 198.6± 16.7 0.48 
LDL, mg/dL 106.4 ± 7.0 129.6 ± 9.2 0.06 104.7± 11.6 103.2± 19.4 0.95 
HDL, mg/dL 51.1 ± 2.4 55.7 ± 4.1 0.34 64.2 ± 7.1 81.6 ± 11.6 0.22 
Triglycerides mg/dL 163.2 ± 35.5 116.7 ± 12.3 0.23 73.8 ± 8.9 84.8 ± 4.6 0.34 
Glucose, µmol/mL 87.4 ± 2.9 89.9 ± 2.7 0.59 85.3 ± 5.2 84.8 ± 5.5 0.95 
HbA1c 5.48 ± 0.1 5.6 ± 0.1 0.22 5.4 ± 0.1 7.2 ± 2.0 0.35 
Insulin, µU/mL 13.5 ± 3.3 12.7 ± 2.5†† 0.84 7.8 ± 1.3 7.0 ± 1.3 0.67 
Syst. BP, mm/Hg 142.2 ± 2.0 126.2 ± 3.8† 0.01 117.0 ± 4.9 123.8 ± 6.4 0.41 
72.0 ± 5.7* Diast BP, mm/Hg 75.8 ± 1.7 69.0 ± 2.2 0.05 58.2 ± 1.7 0.03  
 
 
Values represent mean ± SEM; LDL, low density lipoprotein; HDL, high density lipoprotein, HbA1c, hemoglobin 
A1c; Syst, systolic; Diast, diastolic.  † P < 0.01; * P = < 0.05.  Obese patients had higher systolic and diastolic blood 
pressure compared to controls whereas normal weight controls had higher diastolic blood pressure compared to 
normal weight patients. †† ANOVA reveals obese individuals (patients and controls) were significantly more 
insulin resistant compared to their lean counterparts.   
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 Table 7 Metabolic Characteristics of Patients and Controls 
 Patients Controls  
(N=24) (N=23) P value 
Cholesterol, mg/dL 182.7 ± 8.1 207.7 ± 11.6 0.08 
LDL, mg/dL 102.7 ± 7.7 124.9 ± 6.8* 0.04 
HDL, mg/dL 55.9 ± 3.6 62.8 ± 4.8 0.26 
Triglycerides, mg/dL 132.1 ± 24.4 108.7 ± 12.7 0.41 
Glucose, µmol/mL 86.5 ± 2.6 88.5 ± 2.4 0.57 
HbA1c 5.4 ± 0.11 6.1 ± 0.59 0.20 
Insulin, µU/mL 10.9 ± 2.1 11.7 ± 2.1 0.80 
Syst. BP, mm/Hg 130.2 ± 3.4 129.3 ± 3.6 0.86 
Diast BP, mm/Hg 66.7 ± 1.9 73.3 ± 2.4* 0.04 
 
Values represent mean ± SEM; LDL, low density lipoprotein; HDL, high density lipoprotein, HbA1c, 
hemoglobin A1c; Syst, systolic; Diast, diastolic. * P = < 0.05.  Controls had higher LDL and diastolic 
blood pressure compared to patients although no other differences were observed.    
 
 
4.2 OBESITY 
4.2.1 Whole Body Fat and Lean Mass 
Neither fat mass, fat free mass, nor percent body fat were different between obese 
patients and controls or normal weight patients and controls (Table 8).  Obese patients had only 
2% more total body fat compared to matched controls whereas normal weight patients were 
1.5% less fat compared to matched controls.  Patients together (obese and normal weight) 
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revealed a trend to have higher FFM compared to controls (Table 9) although no other 
differences were observed in FM or percent body fat.   
Although the number of subjects in this study was small, data were examined to 
determine whether generalized obesity was related to insulin resistance.  The proportion of total 
body fat was not associated (P=0.19) with insulin resistance determined by HOMA (R2=0.05) 
when patients and controls were combined (Figure 3).  Additionally, abdominal fat mass 
indicated no differences between patients and controls. 
 
 
Table 8 Generalized Body Composition in Obese and Normal Weight Women 
Obese Normal Weight   
 Patients Controls P Value Patients Controls PValue 
% BF 48.7 ± 1.0 46.9 ± 1.2 0.26 31.9 ± 3.0 33.4 ± 2.2 0.69 
Fat Mass (kg) 48.4 ± 2.8 42.1 ± 3.1 0.16 21.2 ± 2.2 20.6 ± 2.3 0.75 
Fat Free Mass (kg) 47.6 ± 1.5 44.2 ± 2.0 0.06 42.0 ± 1.9 38.1 ± 1.7 0.16 
25.1 ± 1.4 21.9 ± 0.9 0.16 10.0 ± 1.2 9.4 ± 1.1 0.16 AbdominalFatMass (kg) 
 
 
Values are means ± SE.  BF, body fat.  There were no differences observed between groups P=>0.05 although there was a 
trend for obese patients to have more fat free mass than obese controls P = 0.06
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Table 9 Generalized Body Composition between Patients and Controls 
 Patients Controls P Value 
% BF 43.1 ± 2.2 42.9 ± 1.8 0.96 
Fat Mass (kg) 39.3 ± 3.7 35.8 ± 3.3 0.48 
Fat Free Mass (kg) 45.7 ± 1.3 42.4 ± 1.6 0.12 
20.0 ± 2.0 18.3 ± 1.9 0.52 AbdominalFatMass (kg) 
 
 
Values are means ± SE.  BF, body fat.  There were no differences observed between groups P=>0.05 
although there was a trend for patients to have more fat free mass than controls P = 0.12 
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Figure 3 Correlation between HOMA and Percent Body Fat 
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4.2.2 Regional Fat Distribution 
Obese patients had more (P<0.04) total abdominal fat and a trend (P=0.09) toward both 
greater visceral and subcutaneous abdominal fat determined by CT scans (Table 10).  There were 
no differences observed in total abdominal fat or subcutaneous abdominal fat between normal 
weight patients and controls, although there was a trend for normal weight controls to have more 
visceral fat compared to normal weight patients.  Furthermore, there were no differences 
observed in the ratio between visceral vs. subcutaneous abdominal fat between groups.  There 
was an association (P=0.04) between visceral adipose tissue and insulin resistance determined by 
HOMA IR (Figure 4, R2=0.13), in addition to total abdominal fat and insulin resistance (P=0.04, 
R2 2=0.08) and total subcutaneous fat and insulin resistance (P=0.02, R =0.12).  Additionally, 
abdominal fat mass measured by DXA indicated no differences between patients and controls 
(obese= 25.1 ± 1.4 vs. 21.9 ±9 1.7 kg and normal weight = 10.0 ± 1.2 vs. 9.4 ± 1.2 kg).  
Although upon removing an outlier, results revealed a trend between visceral adipose tissue and 
insulin resistance (P = 0.06) no difference between total abdominal fat and insulin resistance, a 
significant correlation between subcutaneous abdominal fat and insulin resistance (P = 0.03, 
R2=0.14).   
Neither total thigh adipose tissue nor intermuscular fat was significantly different 
between obese patients and matched controls or normal weight patients and matched controls 
(Table 10) although there was a trend (P=0.11) for obese patients to have more subcutaneous 
thigh fat compared to matched controls .  There were no differences observed in patients (both 
obese and normal weight) compared to controls, Table 11. 
 44 
  
Table 10 Computed Tomography in Obese and Normal Weight Women 
Obese Normal Weight   
  Patients Controls PValue Patients Controls PValue
Total Abd Fat(cm2 607.4 ± 38.6* ) 718.1 ± 33.6 0.04 261.3 ± 37.3 332.7 ± 46.7 0.26 
Abd.Visceral Fat(cm2) 180.0 ± 11.3 151.0± 16.7 0.09 53.3 ± 8.1 78.5 ± 11.8 0.10 
Abd. Subcutaneous Fat(cm2) 483.2 ± 49.1 445.4 ± 37.7 0.09 207.9 ± 37.0 233.0 ± 23.5 0.60 
Total Thigh Fat(cm2) 219.6 ± 23.7 174.7 ± 18.3 0.15 107.3 ± 16.8 124.5 ± 10.7 0.43 
Subcutaneous Thigh Fat(cm2) 202.6 ± 24.1 153.8 ± 17.3 0.11 95.1 ± 16.2 111.2 ± 9.4 0.44 
Intermuscular Thigh Fat(cm2) 7.0 ± 0.9 6.5 ± 0.6 0.66 1.2 ± 0.3 1.7 ± 0.4 0.38 
Thigh Muscle(cm2) 128.3 ± 3.8 124.6 ± 7.7 0.65 111.5 ± 6.9 101.8 ± 2.9 0.26 
 
 
 
Values are means ± SE.  Abd, abdominal.  Total abdominal fat was significantly higher in obese patients 
compared to controls.  There was a trend for abdominal visceral and subcutaneous fat to be higher in obese 
patients compared to controls although normal weight patients did not display any difference in abdominal 
body composition.  * = P < 0.05 
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Table 11  Computed Tomography in Patients and Controls 
  Patients Controls PValue 
Total Abd Fat(cm2) 556.8 ± 60.0 526.6 ± 43.2 0.69 
Abd.Visceral Fat(cm2) 135.3 ± 17.0 124.4± 14.2 0.63 
Abd. Subcutaneous Fat(cm2) 386.0 ± 47.0 382.9 ± 36.3 0.96 
Total Thigh Fat(cm2) 180.0 ± 20.9 159.9 ± 14.3 0.44 
Subcutaneous Thigh Fat(cm2) 164.7 ± 20.7 141.3 ± 13.3 0.35 
Intermuscular Thigh Fat(cm2) 8.1 ± 0.6 8.2 ± 0.5 0.90 
Thigh Muscle(cm2) 122.4 ± 3.9 117.7 ± 6.0 0.52 
 Values are means ± SE.  Abd, abdominal.  There were no differences observed in abdominal 
adipose tissue or thigh adipose tissue between patients and controls.   
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Figure 4 Correlation between HOMA and Visceral Adipose Tissue 
 
 
4.3 ENERGY EXPENDITURE: 
The secondary aim examined free-living energy expenditure, physical activity and 
nutritional habits in patients with bipolar 1 disorder and matched controls.  Total daily energy 
expenditure did not reveal any differences in obese patients and controls or normal weight 
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patients and controls (Table 12).  Furthermore, active energy expenditure defined as ≥ 2.5 
METS, revealed no differences between obese patients and controls or normal weight patients 
and controls.  Sleep state, based on algorithms provided by BodyMedia, indicated obese patients 
slept more than obese controls (5.7 ± 0.4 vs. 4.2 ± 0.5hr/24hr; P = 0.02, Figure 5) whereas there 
was a trend in normal weight patients sleeping more than controls (7.1 ± 0.8 vs. 5.1 ± 0.4hr/24hr; 
P = 0.07; Figure 6).  Interestingly, there were no differences observed in total time the armband 
was worn (2134.02 ± 117.08hrs vs. 1920.13 ± 122.01hrs, P = 0.22) suggesting that obese patients 
and controls in addition to normal weight patients and controls (2270.33 ± 273.15 vs. 1831.9 ± 
86.61hrs, P = 0.19) wore the armband for equivalent periods of time.   
We additionally examined total energy expenditure, active energy expenditure and sleep 
state during the weekdays and weekends (Table 12).  Neither weekday nor weekend energy 
expenditure or active energy expenditure revealed a significant difference between obese patients 
and controls or normal weight patients and controls.  Whereas obese patients slept significantly 
more on weekdays compared to obese controls (5.1 ± 0.4 vs. 3.4 ± 0.5hr; P = 0.02; Figure 5), 
there was only a trend during the weekends (8.6 ± 1.4 vs. 5.4 ± 0.8hr/24hr; P = 0.06; Figure 5).  
Neither weekday energy expenditure, activity energy expenditure or sleep state were different 
between normal weight patients and controls although there was a trend that normal weight 
patients slept more on weekends than weekdays (8.2 ± 0.7 vs. 6.3 ± 0.5hr/24hr; P = 0.06; Figure 
5). 
Neither the combined patients (obese and normal weight) or combined controls (obese 
and normal weight), revealed any difference in energy expenditure or active energy expenditure 
over the 5 day measurement or during the weekends, Table 13.  There was a trend (P=0.12) 
observed in patients to expend more energy expenditure, though not active energy expenditure, 
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during the weekdays.  There was a significant difference revealing patients slept more overall, on 
weekdays and on weekends compared to controls, Figure 7.  Interestingly, overall the data shows 
patients wore the armband more often than controls indicating a possible explanation for the 
difference in sleep state although during the weekend there were no differences observed in time 
worn but a difference in sleep state was still observed.   
 
  
Table 12 Energy Expenditure Measured via BodyMedia in Patients and Controls 
Obese Normal Weight 
 Patients Controls Pvalue Patients Controls PValue 
Total       
     Time Worn (hrs) 2134.0 ± 117.1 1920.1 ± 122.0 0.21 2270.3 ± 273.2 1831.9 ± 86.6 0.19 
      EE (kcal/24hr) 2208.0 ± 115.8 2106.7 ± 76.0 0.47 2311.3 ±277.7 1891.3 ± 74.0 0.10 
     Active EE (kcal/24hr) 545.3 ± 67.5 519.3 ± 74.6 0.80 741.1 ± 184.5 631.4 ± 124.3 0.65 
Weekdays       
     Time Worn (hrs) 2041.4 ± 96.9 1775.1 ± 116.5 0.09 1880.3 ± 158.8 1645.5 ± 89.0 0.26 
     EE (kcal/24hr) 2108.0 ± 96.4 1933.4 ± 96.9 0.21 1922.8 ± 177.1 1684. 1 ± 79.1 0.28 
     Active EE (kcal/24hr) 476.1 ± 83.4 475.2 ± 86.2 0.99 648.4 ± 184.7 556.8 ± 118.6 0.70 
Weekends       
     Time Worn (hrs) 2487.7 ± 146.7 2266.5 ± 220.0 0.41 2334.5 ± 193.9 2225.6 ± 153.7 0.68 
     EE (kcal/24hr) 2623.2 ± 186.9 2495.6 ± 157.0 0.61 2367.3 ± 198.9 2326.9 ± 106.0 0.87 
     Active EE (kcal/24hr) 656.0 ± 85.5 708.9 ± 173.0 0.79 579.3 ± 227.1 795.1 ± 176.7 0.47 
 
 
Values are means ± SE. EE energy expenditure.  There were no significant differences in EE or active EE 
between obese patients and controls or lean patients and controls.   
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Figure 5 Sleep Duration in Obese Patients and Controls 
 50 
WeekendsWeekdaysAverage
12
10
8
6
4
2
0
Sl
ee
p 
D
ur
at
io
n 
(H
rs
)
Controls
Patients
P=0.07 P=0.29
P=0.06
 
Figure 6 Sleep Duration in Normal Weight Patients and Controls 
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Table 13 Energy Expenditure Measured via BodyMedia in Patients and Controls 
 Patients Controls Pvalue 
Total    
     Time Worn (hrs) 2179.5 ± 116.1 1894.2 ± 88.8 0.06 
      EE (kcal/24hr) 2242.4 ± 116.1 2043 ± 61.7 0.15 
     Active EE (kcal/24hr) 610.6 ± 76.2 552.2 ± 63.2 0.56 
Weekdays    
     Time Worn (hrs) 1987.7 ± 82.8 1737.0 ± 85.9*  0.04 
     EE (kcal/24hr) 2046.3 ± 86.8 1860.1 ± 76.2 0.12 
     Active EE (kcal/24hr) 533.5 ± 82.1 499.2 ± 58.1 0.74 
Weekends    
     Time Worn (hrs) 2436.6 ± 115.2 2254.4 ± 158.9 0.36 
     EE (kcal/24hr) 2537.9 ± 140.7 2446.0 ± 114.7 0.62 
     Active EE (kcal/24hr) 630.4 ± 91.0 734.2 ± 130.1 0.51 
 Values are means ± SE. EE energy expenditure.  There were no significant differences in EE or active EE 
between patients and controls during the 5 day measurement or weekends although there was a trend for 
patients to expend more energy during the weekdays compared to controls. * P<0.05   
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Figure 7 Sleep Duration in Patients and Controls 
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4.4 FATTY ACID METABOLISM 
Neither relative nor absolute rates of fat oxidation were different between obese patients 
and matched controls (Table 14).  Similarly, the proportion of fat utilized at rest was not different 
between obese patients and controls (P = 0.66).  However, absolute (1.2 ± 0.1 vs. 1.8 ± 
0.3mg/FFM/min; P = 0.06) and relative (43.9 ± 4.8 vs. 56.7 ± 6.0%; P = 0.12) rates of fat 
oxidation tended to be lower in normal weight patients than controls.  Normal weight patients 
were oxidizing 13% less fat than matched controls during resting conditions.   
Neither patients (both obese and normal weight) nor controls revealed any differences in 
relative or absolute energy expenditure (Table 15).  There was a trend (P = 0.07) for patients to 
oxidize less fat at rest although relative fat oxidation was not different P = 0.54.  Pearson 
correlation coeffients did not reveal a correlation between fat metabolism and insulin resistance, 
defined by HOMA, for obese (P= 0.481, R2 = 0.02), normal weight (P = 0.439 R2 = 2.7) or the 
combined groups (P= 0.285, R2= 0.004) even when controlling for body composition. 
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Table 14 Resting Rates of Fat Oxidation in Obese and Normal Weight Women 
Obese Normal Weight  
 Patients Controls PValue Patients Controls PValue
Respiratory Quotient 0.83 ± 0.01 0.82 ± 0.01 0.57 0.86 ± 0.01 0.82 ± 0.02 0.13 
EE (Kcal/24h) 1671.1 ± 66.1 1586.3 ± 68.4 0.38 1396.8 ± 50.1 1332.0 ± 45.6 0.37 
-1 1EE (KgFFM min- ) 35.3 ± 1.4 36.1 ± 1.0 0.66 33.5 ± 1.7 35.1 ± 1.3 0.49 
-1/ -1Fatox (mgFFM min ) 1.5 ± 0.1 1.6 ± 0.1 0.49 1.2 ± 0.1 1.8 ± 0.3 0.06 
43.4 ± 5.8 53.4 ± 5.0 Percent Fatox 56.2 ± 3.9 0.66 56.7 ± 6.0 0.12 
-1
 
Table 15 Resting Rates of Fat Oxidation in Patients and Controls 
CHOox(mgFFM /min1) 2.9 ± 0.3 2.7 ± 0.3 0.65 3.4 ± 0.4 3.2 ± 0.6 0.75 
Percent CHOox 46.6 ± 5.0 43.8 ± 3.1 0.66 56.6 ± 5.8 43.2 ± 5.9 0.15 
Values are mean ± SE. EE, energy expenditure; Fatox, fat oxidation, CHOox, carbohydrate oxidation. There 
were no differences observed in EE, relative fat ox or absolute or relative CHO ox although there was a trend 
for normal weight patients to have a lower fat oxidation compared to controls. 
 Patients Controls PValue 
Respiratory Quotient 0.84 ± 0.01 0.82 ± 0.01 0.19 
EE (Kcal/24h) 1579.7± 55.8 1511.5 ±57.1 0.40 
-1 1EE (KgFFM min- ) 34.7 ± 1.1 35.8 ± 0.78 0.43 
-1/ -1Fatox (mgFFM min ) 1.4 ±0.1 1.7 ± 0.1 0.07 
Percent Fatox 50.2 ± 3.8 57.0 ± 3.3 0.20 
-1CHOox(mgFFM /min1) 3.1 ± 0.3 2.9 ± 0.2 0.54 
Percent CHOox 49.8 ± 3.8 43.0 ± 3.3 0.20 
Values are mean ± SE. EE, energy expenditure; Fatox, fat oxidation, CHOox, carbohydrate oxidation. There 
were no differences observed in respiratory quotient or EE although there was a trend for patients to have a 
lower fat oxidation compared to controls.
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4.5 NUTRITION BEHAVIOR 
There were no significant differences in energy intake, protein, fat, carbohydrate or fiber 
intake between patients or controls, Table 16.  Upon examining fat intake specifically, there were 
no differences observed in saturated, monounsaturated or polyunsaturated fat among groups.  
Obese controls consumed a higher proportion of alcohol compared to obese patients (P = 0.03) 
although there was no difference in the proportion of fat, carbohydrates, proteins or sweets.  
Normal weight controls consumed a higher proportion of sweets compared to patients (P = 0.03) 
although proportion of fat, carbohydrates, protein and alcohol were not different.  Overall obese 
and normal weight patients consumed more servings of vegetables compared to controls (P = 
0.04) although servings of fat, fruit, grain, meat and dairy revealed no differences.  
Patients together (both obese and normal weight) consumed more calories, carbohydrates, 
protein, fiber, saturated fat and polyunsaturated fat (Table 17) although surprisingly, they also 
consumed more calcium, dairy and grains compared to controls which have been associated with 
lower levels of weight (Metz, Karanja et al. 1988). 
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Table 16 Nutritional Behavior in Obese and Normal Weight Women 
Obese Normal Weight 
Patients Controls P Value Patients Controls P Value 
Kilocalories (kcal) 2080.1±346.2 1544±282.9 0.24 2030.0±366.0 1833.0±419.5 0.73 
Carbohydrate (g) 237.5 ± 36.5 180.2 ± 37.6 0.29 244.7 ± 49.4 218.0 ± 46.5 0.71 
Fat (g) 94.3 ± 19.3 67.1 ± 12.2 0.25 89.4 ± 16.4 84.1 ± 24.8 0.86 
Protein (g) 78.0 ± 12.0 54.4 ± 9.2 0.13 69.3 ± 13.0 51.4 ± 8.0 0.29 
Fiber (g) 17.0 ± 2.7 11.0 ± 1.9 0.09 17.9 ± 3.5 10.4 ± 1.4 0.10 
Saturated Fat (g) 29.6 ± 5.7 20.9 ± 3.7 0.22 28.2 ± 6.1 26.3 ± 7.7 0.85 
Monounsaturated Fat (g) 37.7 ± 7.7 25.8 ± 4.5 0.20 31.2 ± 5.9 30.8 ± 8.0 0.97 
Polyunsaturated Fat (g) 19.6 ± 4.9 15.4 ± 3.3 0.48 23.2 ± 3.5 21.6 ± 7.7 0.85 
Percent Fat (%) 39.6 ± 2.5 39.3 ± 2.1 0.91 39.9 ± 3.6 38.9 ± 3.0 0.84 
Percent Carbohydrate (%) 46.7 ± 3.0 45.5 ± 2.7 0.77 47.9 ± 3.5 48.3 ± 1.4 0.91 
Percent Protein (%) 15.3 ± 0.9 14.6 ± 0.5 0.53 13.7 ± 0.8 12.1 ± 1.3 0.29 
26.2 ± 3.9* 15.4 ± 3.1 Percent Sweets (%) 16.3 ± 3.7 0.85 13.9 ± 2.7 0.03 
3.04 ± 1.2* Percent Alcohol (%) 0.24 ± 0.2 0.03 0.97 ± 0.6 3.36 ± 1.5 0.14 
Fat Serving 3.5 ± 0.5 3.1 ± 0.5 0.53 3.9 ± 0.5 4.8 ± 1.3 0.51 
Fruit Serving 1.4 ± 1.1 0.9 ± 0.2 0.21 1.5 ± 0.4 0.8 ± 0.1 0.15 
Vegetable Serving 3.1 ± 0.6 1.8 ± 0.2* 0.04 3.7 ± 0.4* 1.6 ± 0.4 0.04 
Grain Serving  5.1 ± 1.1 3.7 ± 1.0 0.32 5.9 ± 2.2 3.1 ± 0.4 0.29 
Meat Serving 2.0 ± 0.5 1.6 ± 0.3 0.52 1.8 ± 0.4 1.2 ± 0.2 0.26 
Dairy Serving 2.2 ± 0.4 1.1 ±0.4 0.06 1.6 ± 0.4 1.2 ± 0.3 0.38 
 
 
Values are mean ± SE.  Obese patients consumed more alcohol and servings of vegetables than controls whereas 
normal weight patients consumed more sweets and servings of vegetables than controls.  * P < 0.05 
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Table 17  Nutritional Behavior in Patients and Controls 
Patients Controls P Value  
Kilocalories (kcal) 2185.0±282.8 1500.2±163.7* 0.05 
171.2 ± 18.4* Carbohydrate (g) 258.9 ± 33.6 0.03 
Fat (g) 98.3 ± 14.3 66.2 ± 9.1 0.07 
52.6 ± 6.3* Protein (g) 75.9 ± 9.1 0.05 
Fiber (g) 17.5 ± 2.3 10.6 ± 0.9† 0.01 
Saturated Fat (g) 30.8 ± 4.3 20.7 ± 2.9 0.07 
Monounsaturated Fat (g) 37.4 ± 5.4 25.3 ± 3.4 0.07 
Polyunsaturated Fat (g) 22.6 ± 3.8 15.3 ± 2.4 0.12 
Percent Fat (%) 40.1 ± 1.9 38.8 ± 1.7 0.62 
Percent Carbohydrate (%) 47.4 ± 43.1 46.0 ±2.1 0.64 
Percent Protein (%) 14.3 ± 0.7 14.3 ± 0.6 0.95 
16.5 ± 2.6 Percent Sweets (%) 17.5 ± 2.7 0.77 
3.3 ± 0.9†† Percent Alcohol (%)  0.3± 0.1 0.001 
Fat Serving 4.1 ±0.5 3.1 ± 0.4 0.15 
Fruit Serving 1.4 ± 0.2 1.0 ± 0.2 0.18 
Vegetable Serving 2.9 ± 0.4 2.1 ± 0.3 0.13 
3.2 ± 0.5* Grain Serving  5.6 ± 1.0 0.05 
Meat Serving 2.0 ± 0.3 1.5 ± 0.2 0.36 
1.5 ± 0.2* Dairy Serving 2.1 ± 0.3 0.04 
 
 
Values are mean ± SE.  Patients consumed more calories, carbohydrates, protein and fiber than controls.  There 
was a trend for patients to consume more fat than controls.  The type of fat intake was not different between 
groups although there was a trend indicating patients consumed more saturated, monounsaturated and 
polyunsaturated fat compared to controls.  Patients also consumed more servings of grain and diary compared to 
controls although controls consumed more alcohol compared to patients.  * P < 0.05 † P < 0.01 †† P < 0.001 
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5.0 CHAPTER 5   
5.1 DISCUSSION 
 
5.1.2 Insulin Resistance 
Bipolar disorder has been associated with an increased prevalence of type 2 diabetes.  
One of the primary characteristics of type 2 diabetes is insulin resistance, which has been linked 
to hypertension, dyslipidemia and cardiovascular disease.  Obesity, especially abdominal obesity, 
is a common thread among metabolic disorders (Reilly and Rader 2003) as well as 
cardiovascular disease (Haffner 1997; Lempiainen, Mykkanen et al. 1999) and is also strongly 
associated with insulin resistance (Goodpaster, Thaete et al. 1997).  Individuals suffering from 
mental health diseases have higher prevalence of obesity (Fagiolini, Frank et al. 2002; Fagiolini, 
Kupfer et al. 2003; McElroy, Kotwal et al. 2004), diabetes (Russell and Johnson 1981; Cassidy, 
Ahearn et al. 1999; Regenold, Thapar et al. 2002), dyslipidemia (Yates and Wallace 1987; 
Atmaca, Kuloglu et al. 2002), hypertension (Elmslie, Silverstone et al. 2000), and cardiovascular 
disease (Elmslie, Silverstone et al. 2000; 2001; Lakka, Laaksonen et al. 2002) than the general 
population.  It was reasonable therefore to examine whether patients with bipolar disorder are 
more insulin resistant than can be expected on the basis of their level of obesity alone.  
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A key finding in this study was that patients with bipolar disorder were no more insulin 
resistant than race, age and BMI-matched controls.  Although the prevalence of obesity and type 
2 diabetes is generally higher in these patients, insulin resistance has not yet been examined 
directly in bipolar disorder.  Thus, this is the first study to our knowledge that has examined 
insulin resistance in these patients.  
There are several possibilities as to why differences in insulin resistance were not 
observed between patients and controls.  One likely explanation is that obesity may be the 
primary driving force in the association with insulin resistance, and that bipolar disorder itself is 
not associated with insulin resistance independent of obesity. In other words, once these patients 
become obese, they are no more insulin resistant than women without bipolar disorder. Indeed, 
both obese patients and controls were substantially more insulin resistant than normal weight 
women. However, that does not discount the possibility that bipolar disorder contributes to 
obesity. Obtaining a ‘snapshot’ in one point in time of patients with bipolar disorder and controls 
in a cross-sectional comparison does not permit conclusions to be drawn concerning whether or 
not bipolar disorder contributed to their obesity. The possibility that characteristics of normal 
weight patients may predispose them to weight gain will be discussed later.   
It is possible that the estimate of insulin resistance in this study was inadequate. The 
Homeostatic model assessment of insulin resistance (HOMA IR) is only a surrogate for insulin 
resistance.  Although HOMA IR is correlated with more direct measures of insulin resistance, for 
example, with the hyperinsulinemic euglycemic clamp method, this estimate of insulin resistance 
may not have been adequately sensitive to detect more severe insulin resistance in a small 
number of bipolar patients examined in this study.  In support of this, abdominal fat content, a 
strong correlate of insulin resistance, (Jensen, Kanaley et al. 1995) was higher in patients 
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compared to controls. This suggests the possibility that these patients were indeed more insulin 
resistant. Future studies using more sophisticated techniques to quantify insulin resistance in 
these patients are warranted.  
Another factor that may have confounded the ability to detect differences in insulin 
sensitivity between patients and controls was medication use by patients.  Certain medications 
such as olanzapine and clozapine have been shown to not only increase weight but also increase 
risk of diabetes (Wirshing, Wirshing et al. 1999).  However, this could not have contributed to 
insulin resistance in this study since potential volunteers using these medications were excluded 
from this study.  Not even a lifetime history of treatment with these specific medications was 
allowed.  In addition, not all medications used to treat bipolar disorder exacerbate insulin 
resistance.  McIntyre et al (2006) have suggested that some antidepressants may in fact improve 
insulin sensitivity (McIntyre, Soczynska et al. 2006).  Upon a MedLine search from 1966 to 
2005, these authors reported some selective serotonin reuptake inhibitors (SSRI) reduced 
hyperglycemia and normalized glucose homeostasis whereas nonselective hydrazine monoamine 
oxidase inhibitors (MAOI) were associated with hypoglycemia and increased glucose disposal 
rate.  These medications may have confounded the ability to detect differences in insulin 
resistance between patients and controls since these patients were treated with such medications 
prior to and during this study.  These data highlight the need to further examine insulin resistance 
in bipolar disorder in a larger number of subjects using direct measures of insulin sensitivity 
while accounting for the potential influence of medication usage.  
Other parameters of the insulin resistance syndrome, or metabolic syndrome were also 
examined in this study.  Obese patients with bipolar disorder were more hypertensive than 
controls.  This is in agreement with a growing body of literature indicating that bipolar patients 
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are more prevalent to have hypertension than the general population(Kilbourne, Cornelius et al. 
2004; Beyer, Kuchibhatla et al. 2005).  Although majority of research examines this 
characteristic in relation to the metabolic syndrome, the current data indicate based on ATP III 
criteria, that only two patients and one control met criteria for metabolic syndrome.  Only two 
other studies to our knowledge have examined the metabolic syndrome in this population.  Basu 
et al (2004) investigated metabolic syndrome in Schizoaffective Disorder Bipolar Subtype (Basu, 
Brar et al. 2004).  They recruited patients currently partaking in a double-blind study of 
topiramate or placebo as adjunctive treatment.  Basu et al. describe a 42% prevalence rate which 
is similar to the 30% prevalence that was reported by Fagiolini et al (2005) (Fagiolini, Frank et 
al. 2002).   The small sample size in the current study precludes any comparison of prevalence of 
metabolic syndrome to these other studies.  
 
5.2 OBESITY 
5.2.1 Generalized Obesity 
Neither the total body fat, proportion of body fat, nor fat free mass was different between 
groups. This lack of differences was largely driven by the study design; we intentionally 
recruited and matched patients and controls on the basis of body mass index (BMI).  Since BMI 
is highly correlated with generalized obesity, it is highly unlikely that differences in general body 
composition would be observed.  
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5.2.2 Regional Fat Distribution 
CT scans revealed higher amounts of total abdominal fat and trends towards higher 
visceral and subcutaneous abdominal fat in obese patients compared to controls.  These 
differences were not observed in normal weight subjects.  This is in agreement with previous 
reports indicating that bipolar patients were more likely to have abdominal obesity than the 
general population (Elmslie, Silverstone et al. 2000; Fagiolini, Frank et al. 2002; McElroy, 
Kotwal et al. 2004).  However, these studies did not account for total body fat, which can 
confound differences in abdominal fat.  The current results are in disagreement with Weber-
Hamann et al. (2002) who used computed tomography to assess visceral adiposity in depressed 
postmenopausal women.  Differences in visceral adiposity compared to controls were not 
observed.  Methodology between the two studies is slightly different though this could unlikely 
account for the discrepancy.  Weber-Hamann and associates analyzed a single slice at each L1 
and L4 whereas we used a single slice in-between L4 and L5.  Furthermore, the patient 
population is different.  Though it has been shown that majority of bipolar patients stay longer in 
depressed state compared to manic state (Judd, Schettler et al. 2002; Judd and Akiskal 2003), our 
current population was recruited in euthymic state whereas in the aforementioned study, authors 
recruited women with at least a score of 18 on the Hamilton Depression Scale which indicates a 
moderate to severe state of depression.  No other study to our knowledge has examined 
abdominal adiposity in bipolar patients using CT or other imaging modalities such as MRI.  
Abdominal obesity has more typically been examined in disorders of mental health using 
a more common estimate of abdominal obesity such as waist circumference.  For instance, 
Fagiolini et al. (2005) obtained waist circumference values on 171 patients with bipolar disorder 
from the Bipolar Disorder Center for Pennsylvanians (Fagiolini, Frank et al. 2002).  They 
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reported that 49% of patients met criteria for abdominal obesity using waist circumference as the 
primary measure.  Waist circumference has been shown to be correlated to visceral adiposity 
more so than waist to hip ratio (Pouliot, Despres et al. 1994) although it appears to have a higher 
correlation to total body fat rather than visceral fat (Harris, Visser et al. 2000).  This is in accord 
with the current results indicating obese patients had higher total abdominal fat compared to 
controls whereas only a trend was revealed for differences in visceral adiposity.   
5.3 ENERGY EXPENDITURE 
Resting metabolic rate was not different between patients and controls.  Obesity is a 
paramount public health concern because it is a primary risk factor for cardiovascular disease 
and type 2 diabetes.  Many factors have contributed to this dramatic increase in obesity, but from 
a physiological perspective, this problem can be reduced to the very simple concept of energy 
balance.  A positive energy balance leads to excess body fat and obesity is due to either an 
increase in energy intake, (i.e. overeating), or a decrease in energy expenditure, or likely a 
combination of both.   
This is the first study to our knowledge that has examined energy expenditure in patients 
with bipolar disorder.  We did not detect any differences in resting energy expenditure, resting 
metabolic rate or active energy expenditure between obese patients and controls or normal 
weight patients and controls indicating reduced energy expenditure may not be the underlying 
cause of their increased risk for obesity.  Previous studies have examined physical activity levels 
in bipolar disorder using self report measurements.  For instance, Elmslie et al (2001) identified 
lifestyle related factors through the LINZ activity questionnaire among patients with bipolar 
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disorder and reference subjects matched for age and race for 4 weeks preceding study 
measurements.(Elmslie, Mann et al. 2001) These authors reported that patients participated in 
fewer low to moderate intensity and high intensity activities compared to reference subjects.  In 
contrast, another study conduced by Davidson et al. (2001) examined patients with mental illness 
defined as schizophrenic, schizoaffective or bipolar.(Davidson, Judd et al. 2001)  Authors 
examined, through self report from the Risk Factor Prevalence Study,(Health 1991) that patients 
were more likely to walk for exercise compared to non-patient participants.  Comparisons of 
studies are problematic for two reasons: subject matching and methodology.  For instance, 
Elmslie et al compared bipolar patients to reference subjects based on age and race, not BMI.  
BMI in addition to body composition is an important factor to consider when controlling for 
activity level since it has been shown to correlate with BMI.119  Secondly Elmslie and associates 
and Davidson and associates used self report measurements whereas the current project assessed 
overall caloric expenditure.  Though the participants in the previous two studies may report 
lower or higher exercise habits they do not measure 24 hour energy expenditure which is an 
important factor to consider in respect to obesity.   
The only study using more objective measurements was a study conducted by Harvey et 
al (2005) examining sleeping patterns in bipolar patients using an accelerometer (Actigraph) for 
8 consecutive days. (Harvey, Schmidt et al. 2005)  Harvey et al. (2005) reported that bipolar 
patients had a reduced activity level during the day time although concludes this may have been 
due to their medications in addition to their insomnia.  For instance, lower activity levels during 
the day may serve to protect against the lack of sleep the night prior.  The discrepancy between 
Harvey et al. and the current project is matched controls and methodology.  Harvey’s group 
divided patients among sleeping characteristics and control subjects were not matched based on 
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body composition nor BMI.  The current project used the BodyMedia SenseWear Armband 
which has provided valid and reliable estimates of energy expenditure at rest and also generates 
similar estimates of energy expenditure as indirect calorimetry.(Fruin and Rankin 2004)  Another 
important consideration in assessing energy expenditure is that many instruments, including self 
reported activity as well as accelerometry may not capture lower levels of activity, which may be 
important in overall health125.  Thus an important aspect of this project was that a novel method 
was used to capture lower levels of activity in addition to supporting the idea that patients 
increased risk for obesity may not be associated with their lack of overall caloric expenditure, at 
least in respect to euthymic bipolar patients.   
The BodyMedia armband did reveal obese patients sleeping more hours of the day over 
the entire 5 day period and on weekdays though only a trend was observed on weekends.  
Though the data only revealed a trend, normal weight patients also slept more overall and on the 
weekends.  BodyMedia SenseWear armband utilized in this study used Innerview V4.1 
algorithms and was designed to measure 24 hour use.  The accuracy, determined using "by 
subject" cross validation from a group of subjects at The University of Pittsburgh hospital sleep 
lab and another group of subjects who supply self reported activity annotations.  Validation data 
has not been published as of today using these specific 24 hour algorithms although one study 
conducted by Germain et al (2006) examined the validity of the BodyMedia armband in 
assessing wakefulness, REM sleep and NREM sleep126.  Authors revealed the algorithm correctly 
identified 93% of all sleep epochs, and 83% of all wakefulness epochs, for an overall epoch-by-epoch 
accuracy of 89%.   
Interestingly, bipolar patients slept more often which is in contrast to some previously 
reported data.  Harvey et al (2005) reported 75% of bipolar patients had a significant lack of 
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sleep problem whereas 55% met diagnostic criteria for insomnia.(Harvey, Schmidt et al. 2005)  
The discrepancy in sleep duration between this study and Harvey et al. can be in the 
methodology.  Actigraph has been shown to be reliable in individuals without sleep complaints 
although has a lower reliability in individuals who lie immobile for long periods.   
These noninvasive measurements of energy expenditure may be important in future 
studies to determine the importance of the various components of energy expenditure, including 
physical activity and sleep patterns, which may contribute to metabolic dysregulation in bipolar 
patients. Perhaps future studies using more objective measures of energy expenditure, such as 
doubly labeled water method, would be useful to determine whether patients with bipolar 
disorder have reduced physical activity or daily energy expenditure.  
5.4 FATTY ACID METABOLISM 
Fat oxidation after an overnight fast, a correlate of insulin resistance in previous studies 
(Kelley, Goodpaster et al. 1999), was similar in obese patients and controls.  Interestingly, 
however, normal weight patients tended to have a lower fat metabolism compared to controls.  
This is the first study to show that pre-obese bipolar patients may utilize a lower proportion of fat 
during basal conditions compared to controls.  This finding may provide important insight into 
the factors that may contribute to weight gain and obesity in patients with bipolar disorder. An 
impaired capacity to utilize fat is related to increased weight gain and insulin resistance (Kelley, 
Goodpaster et al. 1999).  Patients with bipolar disorder are often more obese than the general 
population and a reduced capacity to utilize fat at rest is linked to increased weight gain.  This 
reduced fat oxidation may be an underlying factor contributing to their increased risk for obesity.  
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Future prospective studies are needed to examine factors, including an impaired capacity for fat 
oxidation, which may predispose these patients to weight gain. It is possible that lifestyle factors, 
including physical activity and diet, as well as medication usage, may be underlying factors for 
altered fuel metabolism in bipolar disorder. 
5.5 NUTRITION BEHAVIOR 
The prevalence of obesity in the United States increased from 14.5% to 30.9% during 
1971—2000 (Flegal, Carroll et al. 2002).  Unhealthy diets and sedentary behaviors have been 
identified as the primary causes of deaths attributable to obesity (Services. 2001).  Evaluating 
trends in dietary intake is an important step in understanding the factors that contribute to the 
increase in obesity.  Although there were no differences observed in energy intake, carbohydrate 
or fat consumption, obese patients consumed over 500 more calories than controls and normal 
weight patients consumed over 200 more calories than controls.  These results are in agreement 
with Elmslie et al (2001).  Elmslie and associates examined 24-hour diet recall and also a 4 day 
estimate of nutrient intake.  Authors report women with bipolar disorder had a higher energy 
intake, though not significant, compared to reference subjects.  At first glance this would appear 
clinically significant although energy expenditure as measured in the current study, was also 
slightly higher in bipolar patients compared to controls.  This would be expected since obese 
patients were slightly larger than obese controls.  Elmslie et al. did not examine 24-hour energy 
expenditure therefore it cannot be concluded that the importance of their results in respect to 
their level of obesity.  Furthermore, the methodology of the study conducted by Elmslie et al. 
also did not take into account body composition differences.  It is difficult to compare energy 
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intake to reference subjects if you do not control for differences in body mass.  Individuals with 
higher body mass would be expected to consume more calories compared to smaller body 
masses.  It would have been nice to quantify the effects of dietary intake specific to medications 
however the number of subjects in each medication category were too small to allow me to draw 
any definitive conclusion about examine the contributions of medications. 
5.6 SUMMARY AND CONCLUSIONS 
A key finding from this study was that, in patients with bipolar disorder, obesity is a 
stronger influence on insulin resistance than is bipolar disorder itself. In other words, insulin 
resistance in these patients does not appear to be more severe after accounting for their obesity. 
This conclusion, however, should be tempered by the observation that these obese women with 
bipolar disorder had significantly more abdominal fat and were slightly more hypertensive than 
BMI-matched controls, allowing for the possibility that bipolar disorder may indeed be 
associated with altered metabolic profile.  
Using tools to assess both energy expenditure and energy intake, this project indicates 
that, once these euthymic patients with bipolar disorder become obese, their energy imbalance is 
likely similar to non-patient controls. However, similar levels of insulin resistance in patients 
compared to BMI-matched controls in this cross-sectional study do not discount the possibility 
that bipolar disorder does not somehow predispose these patients towards weight gain and 
obesity.  Comparing normal weight subjects perhaps provides some important clues in this 
regard. 
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Another finding in this study was that normal weight patients with bipolar disorder 
tended to have reduced rates of fat oxidation after an overnight fast. Thus, it is possible that 
reduced rates of fat oxidation in pre-obese patients might contribute to greater weight gain in 
these patients. However, the physiological factors that may contribute to weight gain to cause 
them to become more obese than the general population remain unknown.  Future prospective 
longitudinal studies are needed to address this hypothesis. 
An important practical implication of the current study was that we were was able to 
recruit individuals diagnosed with the most severe form of bipolar disorder who were then able 
to tolerate and complete all procedures.  This is the first study to show the feasibility of 
performing body composition and metabolic assessments in patients with bipolar disorder. Thus 
the demands of these specific studies are achievable in this patient population. Therefore, these 
tools may be useful to address important questions concerning the effects of lifestyle 
modifications, including diet and exercise programs, on obesity prevention and treatment in 
bipolar disorder. 
5.7    LIMITATIONS AND FUTURE DIRECTION 
The primary limitation of this study is the cross-sectional comparisons of patients and 
controls. The potential for lower rates of fat oxidation in pre-obese patients raises the possibility 
that there are underlying factors which contribute to weight gain and obesity in bipolar disorder, 
which could be addressed in a future prospective longitudinal study. Another limitation is that a 
small number of patients were studied; making it impossible to ease out any potential effect that 
specific medication usage might have on metabolic risk profile. With greater numbers of patients 
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on different medication regimes we could then begin to tease out medication effects from the 
disorder itself. 
Another limitation in this study was the indirect assessment of insulin resistance.  Given 
the higher abdominal fat content in obese patients, it is possible that our surrogate for insulin 
resistance was not adequately sensitive to detect differences in insulin resistance in patients 
compared to controls. More sophisticated measurements of insulin resistance, such as glucose 
tolerance testing or glucose clamp methodologies, could be employed to examine this possibility. 
Future studies should be performed to examine specific medication affects on insulin 
resistance, understanding the effects of medications, such as antipsychotics and antidepressants, 
will help determine if the potential contributor of insulin resistance lies in the disorder itself or if 
insulin resistance has been induced through treatment.  The effects of reduced fat metabolism 
can increase the risk and rate at which an individual gains weight.  It is important to determine if 
this is an underlying cause to their risk for obesity and then determining whether lifestyle 
modification, including diet and exercise, can be effectively implemented in obese patients with 
bipolar disorder.  Our future goals include a line of investigation that will examine the effects of 
physical activity and weight loss intervention on insulin resistance, regional fat distribution and 
fuel metabolism.  Critical information would be gained to determine whether these patients can 
achieve similar benefits as obese men and women in the general population, or alternatively, 
whether there are underlying psychosocial or physiological factors causing them to be resistant 
to change 
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Why is this research being done?  
This research study is asking the question if individuals diagnosed with Bipolar I 
Disorder are different from individuals not diagnosed with any form of Bipolar Disorder 
in regards to body fat, the hormone insulin, resting metabolism and physical activity 
levels. You will be asked to visit Montefiore Hospital two different times.  The first visit 
will assess how your body uses insulin, that is, how your body responds to the hormone 
insulin.  The second visit will assess where your body stores visceral (fat around your 
organs) and subcutaneous fat (fat under your skin).  You will also be asked to wear an 
armband to determine your physical activity levels for 5 days in between visit 1 and visit 
2.  These studies should provide further direction on the cause of insulin resistance (your 
body’s ability to use blood sugar) in subjects who have been diagnosed with bipolar 
disorder, who are at a higher risk for the development of obesity and type 2 diabetes (a 
metabolic disease that involves the hormone insulin).    
Who is being asked to take part in this research study?   
You are being invited to participate in this research study because you have 
already been diagnosed with bipolar disorder.  Subjects are being recruited from the 
clinics at Western Psychiatric Institute and Clinic (WPIC).  Subjects invited have to be 
between 18-60 years of age and, cannot be pregnant, are either of normal weight or 
moderately overweight based on your height and weight or Body Mass Index {your height 
in kilograms divided by your weight in meters (≤ 25kg/m2 or ≥ 30kg/m2)}, and have not 
gained or lost >5kg (12.7lbs) within the past month.  If you qualify you will be one of up 
to 60 subjects in this study.  Participation in the study will last 7 days and will include two 
visits to the hospital and 5 days of wearing an armband to assess your activity level. 
 
What procedures will be performed for research purposes?   
If you agree to participate in this study, you will undergo the following procedures 
that are not part of your standard medical care:  
Screening Procedures:   
 
Procedures to determine if you are eligible to take part in this research study are 
called “screening procedures.” For this study, the screening procedures include: 
Screening Visit #1: (approximately 2 hours in length)
1. You will be asked to provide some background information about your general 
medical history (a thorough review of your health history) and your psychiatric 
illness.   
2. You will be asked to complete a questionnaire that is going to inform us about 
your nutritional habits.  Specifically, this questionnaire will measure how you 
prepare your food and the amount of food you typically eat. Overall, this 
questionnaire will allow us to estimate the average daily calories you intake of 178 
different food items.  
3. Fasting (nothing by mouth except water for 10-12 hours prior) screening 
laboratory work that includes a CBC (complete blood count); electrolytes (salts or 
chemicals in the blood like sodium, potassium, chloride, and carbon dioxide); liver 
function tests (Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) 
and , Alk phos which are substances in blood that is measured to check for liver 
disease) thyroid function (TSH, measures your thyroid gland in the neck which is 
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important in controlling metabolism); and blood glucose (sugar) levels (fasting 
glucose and HbAlc – a number that tells us approximately what your blood sugar 
has been for the past three months); insulin levels; blood fat levels (Fat and 
cholesterol levels in the blood such as cholesterol, HDL, LDL, VLDL, 
triglycerides); and kidney function (blood urea nitrogen {BUN}, creatinine, and 
urinalysis {series of tests done on urine} will determine the kidney ability to filter 
blood). About 2 tablespoons (one ounce) of blood will be drawn to complete the 
screening labwork.   
A copy of this consent (agreement) document and all laboratory results will be 
given to you. You are free to share these records with anyone of your choosing.  To be 
eligible for this study, you must be free of proteinuria {protein in your urine (defined as 
>1 + on routine dipstick)}, hypothyroidism (your thyroid hormone does not work well), 
medications such as thiazide (promote water loss from the body), diuretics (help the body 
get rid of water and salt), oral glucocorticoids (steroid hormones), nicotinic acid {also 
known as niacin (vitamin B2)}, or hormone replacement therapy (the use of estrogen and 
progesterone from an outside source). You also will be excluded if you have taken 
previously or are currently taking olanzapine or clozapine (antipsychotic medication used 
to treat some psychiatric illnesses).  
In the event that a clinically significant, unanticipated disease or condition is 
identified during the screening exam, you will be made aware, will be given a copy of the 
screening lab work and will be instructed to contact your primary care physician for 
follow-up.  
 
Physical Activity Measurement following Visit 1: (approximately 5 days in 
length): 
Immediately following your blood draw during visit one, you will be given an arm 
band called a SenseWear Pro to wear on your right arm for five days.  This will be used to 
measure energy expenditure (how many calories you burn) for five days while you 
perform regular daily activities such as sitting and sleeping.  You will be instructed not to 
remove the armband at anytime (excluding showering) unless irritation occurs.  If 
irritation occurs, immediately take the armband off and see your doctor.   
 
Metabolic Measurements Visit #2: (approximately 2 hours in length)
1. You will be instructed to return after an overnight fast (nothing by mouth except 
water for 10-12 hours prior), and to minimize as much movement as you can the day 
of the test.  For an example, you will be instructed to take the elevator instead of the 
stairs.  When you arrive, you will be instructed to lay down on a bed for 30 minutes 
to allow your body to return to rest.  A clear plastic hood will be placed over your 
face and neck to collect your exhaled air (the air you breathe out) while you lie face 
up in the bed. This measurement is called indirect calorimetry and is done to 
measure your metabolic rate (amount of oxygen your body uses and how much fat 
and glucose it is burning).    
2. Following, you will have computed tomography scans (CT scans) of your abdomen 
(belly), and mid-thigh to measure the amount of fat in each location. Computerized 
tomography (CT scan) is a method to take pictures of internal organs using X-rays. 
The CT scanner is located at Presbyterian University Hospital.  The CT scanner 
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looks like a donut shaped x-ray machine.  CT scanning is an x-ray that will provide a 
3 dimensional (3-D) picture of your belly and thigh. You will be asked to lie on the 
CT exam table for about 20 minutes while the CT scanning is being done.  
3. Upon a light lunch, you will have a measurement of your body’s fat and muscle 
content.  In order to measure this, you will have a non-invasive scan performed 
which is called a "DEXA" or “dual-energy x-ray absorptiometry” scan which is a 
measure of the structure of the bones.  This scan is performed similar to an x-ray 
study.  You will lie still (not moving) on a firm table for 15 minutes while the DEXA 
scanner moves over your body measuring your fat and fat free mass.   The test is 
painless except for any discomfort you may experience on your back because of 
thlying on the firm examination table. The DEXA scanner is located on the 8  floor of 
Montefiore Hospital.  All women of child-bearing potential (i.e., women who are not 
at least 1 year post-menopause or who have not undergone a surgical sterilization 
procedure) will be tested for pregnancy (via urine sample) within 48 hours prior to 
the DEXA procedures and within 48 hours prior to the CT scans.  Women who test 
positive for pregnancy or are breast feeding will not be permitted to undergo 
these procedures.  Below is a chart made to outline the specific visits you will be 
asked to complete. 
 
Table 2  
 
What are the possible risks, side effects, and discomforts of this research study?  
Participation may entail some risks. Information on the frequency of possible risk 
has been categorized using the following categories: Likely – occurs in more than 25% of 
Visit 1 
(Wednesday) 
Energy Expenditure  Visit 2 
(5 days) (Monday) 
Questionnaires- Energy Expenditure Resting 
Metabolic Rate SenseWear Pro  • Demographic 
Questionnaire • Fat oxidation 
• Carbohydrate 
oxidation 
• Food Freq. 
Questionnaire 
 
Blood Draw Computed 
Tomography 
 
• Blood Lipid (fat) 
Profile • Visceral Adiposity 
• Glucose/Insulin 
• Electrolytes, general 
chemistry profile, 
blood count, sTSH 
  Dual X-ray 
Absorptiometry 
• Fat Free Mass 
• Fat Mass 
Total 
Time: Total Time: Total Time: 2 Hours 2.5Hours 5 Days 
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people (more than 25 out of 100 people); Common – occurs in 1% to 25% of people (1 to 
25 out of 100 people); Rare – occurs in less than 1% of people (less than 1 out of 100 
people). As with any investigational study, there may be adverse events or side effects that 
are currently unknown and it is possible that certain of these unknown risks could be 
permanent, serious or life threatening. The known risks are:   
1) Blood sampling: The risks of blood sampling are common (occurs in 1% to 
25% of people) and may include bleeding, bruising, soreness, dizziness and fainting. 
Infection from the blood sampling is rare (less than 1% of people).  In our experience 
using similar protocols, subjects have not experienced adverse effects from these 
procedures other than a small amount of residual localized soreness at the blood sampling 
area.  
2) DEXA Scan:  Participation in this study involves a minimal amount of radiation 
exposure from the DEXA.  The DEXA scan “whole body” exposure is 2mREM per total 
body scan which is consistent with previously published data concerning this method. For 
comparison, this radiation exposure is a small fraction of the annual whole body radiation 
exposure (300mREM) that each member of the public received from background 
radiation.  There is no minimum level of radiation exposure which is recognized as being 
totally free of the risk of causing genetic mutations (abnormal cells) or cancer.  However, 
this risk associated with the radiation exposure received from participation in this research 
study is considered to be low when compared to everyday risks.  
3) CT Imaging: The CT scan will expose you to a small amount of radiation.  The 
doses are expressed as the effective dose equivalent which weights the radiation dose 
according to volume and type of tissue irradiated and as such, provides a better estimate of 
risk than the surface dose.  The units are microSievert (FSv) which is the standard SI unit 
for the effective dose equivalent (FSv= 0.1 mrem; 1mrem= 10 fSv). The estimated 
effective dose equivalent for the hip is 4-5 uSv and the whole body measurement is 10-15 
fSv (1.0-1.5 mrem).  The CT is associated with exposure to the thigh and abdomen to 
approximately 2030 mrem of absorbed dose.  For comparison, a round trip 
transcontinental flight has an effective dose of 60 fSv (6mrem).  This is substantially less 
than the annual radiation exposure limit of 50,000 mrem to the whole body for radiation 
workers allowed by federal regulation.  This amount of radiation is small and the risks 
from exposure are so small that they are difficult to measure. 
4) Indirect Calorimetry: During indirect calorimetry a test to measure 
metabolism collecting expired oxygen and carbon dioxide) testing, individuals may 
become claustrophobic (rare; occurs in less than 1% of people).  If claustrophobia occurs, 
the hood will be removed. 
5) SenseWear Pro2   Armband: This device worn on the back of the arm may 
cause some skin irritation and redness (rare; occurs in less than 1% of people).   
“What are possible benefits from taking part in this study?” 
 At the end of your research participation, clinical information obtained from the 
research project relevant to your care will be shared with you.  There is no guarantee that 
your participation will directly benefit you.  However, your participation may provide 
useful information that will help future patients suffering from bipolar disorder. 
“If I agree to take part in this research study, will I be told of any new information that 
may be found during the course of the study?” 
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You will be promptly notified if any new information develops during the conduct 
of this research study which may cause you to change your mind about continuing to 
participate. 
“Will I or my insurance provider be charged for the costs of any procedures performed 
as part of this research study?” 
 There are no costs to you or to your insurance provider for the screening 
evaluation, the screening lab work, the Obesity Nutrition Research Center visits, 
laboratory tests, the CT scans, or the DEXA scan. The study will cover the costs of all 
research services.  You and/or your insurance provider will be responsible for any routine 
care costs, including any applicable co pays, coinsurances and deductibles. 
“Will I be paid if I take part in this research study?” 
You will be given reimbursement for participation.  To help defray the costs of 
your participation, you will be compensated a total of $180 if you complete the entire 
study.   An honorarium in the amount of $50 for the completion of screening procedures 
and another $130 if experimental procedures are completed will be given to you for time 
spent away from work, travel, childcare or related costs.   You will also be reimbursed up 
to $10 for transportation/parking and you will receive a copy of all results. 
 
Visits Visit 1 Visit 2 
Payment, $ 50 130 
“Who will pay if I am injured as a result of taking part in this study?” 
University of Pittsburgh researchers and their associates who provide services at 
the UPMC recognize the importance of your voluntary participation in their research 
studies.  These individuals and their staffs will make reasonable efforts to minimize, 
control, and treat any injuries that may arise as a result of this research.  If you believe that 
you are injured as a result of the research procedures being performed, please contact 
immediately the Principal Investigator or one of the co-investigators listed on the first 
page of this form. 
 
 
Emergency medical treatment for injuries solely and directly related to your 
participation in this research study will be provided to you by the hospitals of the UPMC.  
It is possible that the UPMC may bill your insurance provider for the costs of this 
emergency treatment, but none of these costs will be charged directly to you. If your 
research-related injury requires medical care beyond this emergency treatment, you will be 
responsible for the costs of this follow-up care unless otherwise specifically stated below. 
There is no plan for monetary compensation. You do not, however, waive any legal rights 
by signing this form. 
 
“Who will know about my participation in this research study?”  
Any information about you obtained from or for this research study will be kept as 
confidential (private) as possible. You will not be identified by name in any publication of 
research results unless you sign a separate form giving your permission (release).   
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All records related to your involvement in this research study will be stored in a 
locked file cabinet. Your identity on these records will be indicated by a case number 
rather than by your name, and the information linking these numbers with your identity 
will be kept separate from the research records. Access to your research records will be 
limited to the researchers listed on the first page of this form and the study sponsor 
(Western Psychiatric Institute & Clinic Seed Proposal), who may need to review the 
records for accuracy and completeness.  Representatives of the study sponsor may also be 
present during your participation in the research study. The fact that you are participating 
in a research study and that you are undergoing certain research procedures (but not the 
results of the procedures) may also be made known to individuals involved in insurance 
billing and/or other administrative activities associated with the conduct of the study.  
University of Pittsburgh policy states that your research records must be maintained for at 
least five years after study completion.  The researchers conducting this study have chosen 
to maintain your research records indefinitely.  
 
“Will this research study involve the use or disclosure of my identifiable medical record 
information? 
This research study will involve the recording of current identifiable medical 
information from your hospital records.  The information that will be recorded will be 
limited to information concerning your screening laboratory work and study participation.  
This information will be used for the purpose of determining whether you qualify, based 
on study specific inclusion/exclusion criteria, for study participation. This research study 
will result in identifiable information that will be placed into your medical records held at 
the University of Pittsburgh Medical Center.   The nature of the identifiable information 
resulting from your participation in this research study that will be recorded in your 
medical record possibly may include your screening laboratory work. 
 
 
“Who will have access to identifiable information related to my participation in this 
research study?”  
 In addition to the investigators listed on the first page of this authorization 
(consent ) form and their research staff, the following individuals will or may have access 
to identifiable information (which may include your identifiable medical record 
information) related to your participation in this research study:   
 
1)  Authorized representatives of the University of Pittsburgh Research Conduct 
and Compliance Office may review your identifiable research information (which may 
include your identifiable medical record information) for the purpose of monitoring the 
appropriate conduct of this research study.  
 
2)  In unusual cases, the investigators may be required to release identifiable 
information (which may include your identifiable medical record information) related to 
your participation in this research study in response to an order from a court of law.  If the 
investigators learn that you or someone with whom you are involved is in serious danger 
or potential harm, they will need to inform, as required by Pennsylvania law, the 
appropriate agencies. 
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3)  Authorized representatives of the UPMC hospitals or other affiliated health 
care providers (such as the General Clinical Research Center) may have access to 
identifiable information (which may include your identifiable medical record information) 
related to your participation in this research study for the purpose of (a) fulfilling orders, 
made by the investigators, for hospital and health care services (e.g., laboratory tests, 
diagnostic procedures) associated with research study participation; (b) addressing correct 
payment for tests and procedures ordered by the investigators; and/or (c) for internal 
hospital operations (i.e. quality assurance). 
 
“For how long will the investigators be permitted to use and disclose identifiable 
information related to my participation in this research study?”  
The investigators may continue to use and disclose, for the purposes described 
above, identifiable information (which may include your identifiable medical record 
information) related to your participation in this research study indefinitely following 
study completion. 
 
“May I have access to my medical record information that results from my participation 
in this research study?”  
In accordance with the UPMC Notices of Privacy Practices document that you 
have been provided, you are permitted access to information (including information 
resulting from your participation in this research study) contained within your medical 
records filed with your health care provider unless otherwise specifically stated below.  
 
 
“Is my participation in this research study voluntary?”  
Your participation in this research study, to include the use and disclosure of your 
identifiable information for the purposes described above, is completely voluntary.  (Note, 
however, that if you do not provide your consent for the use and disclosure of your 
identifiable information for the purposes described above, you will not be allowed, in 
general, to participate in the research study.)  Whether or not you provide your consent for 
participation in this research study will have no effect on your current or future 
relationship with the University of Pittsburgh.  Whether or not you provide your consent 
for participation in this research study will have no effect on your current or future 
medical care at a UPMC hospital or affiliated health care provider or your current or 
future relationship with a health care insurance provider.  
 
 “May I withdraw, at a future date, my consent for participation in this research study?” 
You may withdraw, at any time, your consent for participation in this research 
study, to include the use and disclosure of your identifiable information for the purposes 
described above.  (Note, however, that if you withdraw your consent for the use and 
disclosure of your identifiable information for the purposes described above, you will 
also be withdrawn, in general, from further participation in this research study.)  Any 
identifiable research or medical record information recorded for, or resulting from, your 
participation in this research study prior to the date that you formally withdrew your 
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consent may continue to be used and disclosed by the investigators for the purposes 
described above. 
          
         To formally withdraw your consent for participation in this research study you 
should provide a written and dated notice of this decision to the principal investigator of 
this research study at the address listed on the first page of this form. 
         Your decision to withdraw your consent for participation in this research study will 
have no effect on your current or future relationship with the University of Pittsburgh.  
Your decision to withdraw your consent for participation in this research study will have 
no effect on your current or future medical care at a UPMC hospital or affiliated health 
care provider or your current or future relationship with a health care insurance provider.  
Your doctor is involved as an investigator in this research study.  As both your doctor 
and a research investigator, he s/he is interested both in your medical care and the conduct 
of this research study.  Before agreeing to participate in this research study, or at any time 
during our study participation, you may discuss your care with another doctor who is not 
associated with this research study.  You are not under any obligation to participate in any 
research study offered by your doctor.  
 
 “If I agree to participate in this research study, can I be removed from the study 
without my consent?”  You may be removed from this research study by the 
investigators in the event that the investigators feel that the study may adversely influence 
your health, if you don't comply with study requirements. 
 
If you do not qualify for this particular study, would you like to be contacted for 
future research studies? They would explain what any additional project studies involve 
before you would agree to volunteer. 
(Please check one) 
   I do not agree to be contacted for future studies. 
   I do agree to be contacted for future studies. 
If you agree to be contacted, please provide a day time phone number where you can be 
reached:    _________________ 
************************************************************************ 
VOLUNTARY CONSENT 
All of the above has been explained to me and all of my current questions have 
been answered. I understand that I am encouraged to ask questions about any aspect of 
this research study during the course of this study, and that such future questions will be 
answered by the researchers listed on the first page of this form.  
 
Any questions I have about my rights as a research participant will be answered by 
the Human Subject Protection Advocate of the IRB Office, University of Pittsburgh (1-
866-212-2668) 
By signing this form, I agree to participate in this research study. A copy of this 
consent form will be given to me.  
___________________________________  ___________________ 
Participant’s Signature      Date  
CERTIFICATION OF INFORMED CONSENT  
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I certify that I have explained the nature and purpose of this research study to the 
above-named individual, and I have discussed the potential benefits and possible risks of 
study participation.  Any questions the individual has about this study have been 
answered, and we will always be available to address future questions as they arise.  
___________________________________                ___________________ 
 Printed Name of Person Obtaining Consent                Role in Research Study 
 __________________________________                    __________________ 
Signature of Person Obtaining Consent                        Date 
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APPENDIX B 
BASELINE DEMOGRAPHIC AND MEDICAL HISTORY FORM 
Date: __ __/ __ __/ __ __   Date of Consent: __ __/ __ __/ __ __ 
 
Rater:  _______________ Subject ID: _______________  Protocol: ______________ 
Height:__ __(inches) __ __ (cm) 
Weight: __ __(lbs.)  __ __ (kg) 
Systolic BP: ____ 
Diastolic BP:_____ 
Sex: 1=Male   2=Female       
 
 
 
RELATIONSHIP 01=Self  
TO SUBJECT: 10=Other 
 
LANGUAGE:  
RELIGION: 
1=Catholic  
2=Protestant* 
1 = English is first language 
2 = English is not first language   
(Native language: ___________) 
 
 
1. MARITAL STATUS 
1 = Single (not presently living with someone of the opposite or same sex for 6 or more 
months) 
2 = Married (or sustained conjugal situation for 6 or more months) 
3 = Separated (if legally married, or apart from common law spouse with chance of returnin 
4 = Divorced (or left common law spouse “for good”) 
5 = Widowed 
2. CHILDREN 
 2a.  Number of biological children (living and nonliving):     __ __ 
 2b.  Number of non-biological children (living and nonliving): __ __ 
3. EDUCATION 
  3a. Total number years of full-time equivalent formal academic education: 
     (from first grade on; not including trade school) __ __ 
4.   CURRENT/MOST RECENT EMPLOYMENT 
3=Jewish  
Subject Type: 
01=Inpatient      02=Outpatient  03=Control 
INSTRUCTIONS:  Complete each item by circling or filling in information which best 
characterizes the subject at time of study entry. 
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 4a. Is subject working in paid employment? 
0 = No  1 =  Yes, Part-time  2=Yes, Full-time 
4b. Number of months in current employment::  __ __ months (0 = not employed) 
4c. If 0 months:  give final date of last employment (at least half-time): __ __/__ __/__ __  
                                                                         (0 = never employed)         MO          DAY          
YR 
4d.   Occupation of current or most recent 
position:______________________________________ 
 
HIGHEST LEVEL OF EDUCATION (Check one for subject, parents and most 
recent spouse, even if separated, divorced or widowed) 
 3b. 
Subject 
3c. 
Mother 
3d. 
Father 
3e. 
Spouse 
    Completed post-graduate training 
    Completed college, received four year 
academic degree 
    Attended college, but did not receive four 
year academic degree 
    Completed HS, trade school or other 
non-academic training requiring HS 
completion for admission 
Partial high school (10th th      or 11  
grade) 
Junior high school (7th th th     , 8 , or 9  
grade) 
Less than 7th      grade 
    Does not apply (no spouse) 
    Information not available (specify why) 
  5. FAMILY EMPLOYMENT 
What is the highest level of occupational attainment achieved by subject, subject’s mother, 
father, and spouse?  (Write in actual occupation below and describe.) 
   5a. Subject: ____________________________________________________________ 
   5b. Mother: ____________________________________________________________ 
   5c. Father: ____________________________________________________________ 
   5d. Spouse: ____________________________________________________________ (if 
applicable) 
   5e-h. Highest level of occupational attainment achieved (use Hollingshead Scale to determine 
occupation level, for occupations that are at least half-time and includes jobs held by 
students)  [NOTE:  "mother" and "father" refer to biological parents, if present during 
subject’s childhood.  If parental surrogate reared subject, code occupation for parental 
surrogate(s).]  See below: 
 
HIGHEST LEVEL OF OCCUPATIONS: (Check one for subject, parents and most 
recent spouse, even if separated, divorced or widowed) 
 5e. 
Subject 
5f. 
Mother 
5g. 
Father 
5h. 
Spouse 
    Higher executives, Proprietors of large 
business (>$250,000) Major professional 
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    Administrators, Lesser professionals, 
Proprietors of medium sized business 
($100-250,000) 
    Small business owners ($75-100,000), 
Farm owners, Mangers, Minor 
professionals 
    Technicians, Semi-professionals, Smaller 
business owners ($50-75,000) 
    Clerical and Sales workers, Very small 
farm and business owner ($25-50,000) 
    Smallest business owners (<25,000), 
Skilled manual worker, Craftsmen and 
Tenant farmers 
    Machine operators and Semi Skilled 
Workers 
    Medial service workers, Dependent upon 
welfare, No regular occupation, Never 
employed 
Does not apply (no spouse)     
 
6. SUBJECT’S LIVING ARRANGEMENT (During one month prior to hospitalization/initial 
assessments) 
1 = Alone     5 = Household of other relative 
2 = Parent household   6 = Household shared with others (non-relatives) 
3 = Own or spousal household  7 = Structured environment (transition housing, 
halfway house) 
4 = Children’s household  8 = Other   Specify:                                             
Pregnancy/Obstetric Complications 
7. Any pregnancy complications (e.g., heavy bleeding, high blood pressure, diabetes, 1 = 
Yes  0 = No 
anemia, seizures, physical injuries, infection requiring medical care, weight gain > 25 pounds)? 
7a.  If yes, explain:________________________________________________________ 
 
8. Any birth problems [e.g., cord around neck, breech, emergency C-section, jaundice,  1 = 
Yes 0 = No blue coloration at birth, absence or irregular breathing, absent crying, small for 
dates, premature birth (> 2 weeks)]?     
8a.  If yes, Explain:__________________________________________________ 
Infancy and Childhood (through 12 years of age) 
9. Significant illnesses/infections affecting CNS function?  1 = Yes 0 = No 
9a.  If yes, explain:______________________________________________________ 
10. Any delay in growth or development?     1 = Yes 0 = No 
10a.  If yes, explain:_____________________________________________________ 
11. Any history of enuresis or encopresis?     1 = Yes 0 = No 
11a.  If yes, explain:_____________________________________________________ 
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12. Any learning difficulties in school?      1 = Yes 0 = No 
12a  If yes, explain:_____________________________________________________ 
13. Any special education?       1 = Yes 0 = No 
13a.  If yes, explain:_____________________________________________________ 
13b-d. If yes, for what? 
     Learning Disabilities  1 = Yes 0 = No 
Mental Retardation  1 = Yes 0 = No 
Emotional Problems  1 = Yes 0 = No 
14. Were you ever held back in school?  1 = Yes 0 = No 
14a.  If yes, explain:______________________________________________________ 
History of head injury 
15.  Ever had a head injury?  1 = Yes           0 =NO (If NO, go to item 11j) 
15a.  If yes, explain:_______________________________________________________ 
15b.  If yes: How many times?    ___ ___ occasions 
15c.   Give age of most severe episode:   ___ ___ 
15d.   What type of injury?  1 = Closed 2 = Open 
16   Any open brain surgery? 1 = Yes 0 = No     
17.  Ever knocked unconscious?  1 = Yes 0 = No   (If NO, go to item 11k) 
17a.  If yes, explain:_______________________________________________________ 
17b.  If yes, how many times?   ___ ___ 
17c.  If yes, for how long (longest duration episode)? ___ ___ minutes 
Major medical problems during adolescence or adulthood (13 years and older) 
18. If subject endorses one or more chronic illnesses, specify below (Circle 1 = “Yes” or 0 = 
“No”) 
   
 YES NO Specify
   
= Epilepsy 1 0  
 
= Asthma 1 
  
0  
 
= Diabetes 1 
  
0  
 
= Cardiac problems 1 
  
0  
 
= Hypertension 
1   
0  
 0  
= Renal disease 1  
 
= G.I. problems 
 
1 
  
0  
= Thyroid problems    
 85 
1 0  
 
= Rheumatological       
   problems 
 
1 
  
0  
 
= Pulmonary problems 1 
  
0  
 
= Other 
____________________  
 
1 
  
0  
= N/A (NONE) 
1 
  
0  
 
19. ESTIMATE TYPICAL DAILY CONSUMPTION OF TOBACCO 
1 = Non smoker            2 = Light (0-10)            3 = Moderate (11-20)            4 = Heavy (21-40 +) 
20. DEVELOPMENTAL HISTORY 
Mother 
20a. What is mother’s age?       ___ ___ (-8 = 
deceased) 
20b. Calculate age of mother when subject was born:   ___ ___ 
Father 
20c. What is the father’s age?       ___ ___ (-8 = 
deceased) 
20d. Calculate age of father when subject was born:    ___ ___ 
Siblings 
20e. How many full siblings does subject have (living and nonliving)?  ___ ___ 
20f. How many half siblings does subject have (living and nonliving)?  ___ ___ 
20g. When was subject born in relation to siblings? 
1 = First  3 = Third    5 = Fifth 
2 = Second  4 = Fourth      6 = Sixth + 
20h. Did any of subject’s siblings die?  1 = Yes  0 = No 
20h-1.  If yes, how old was subject when a sibling died (youngest age applicable)?___ 
___ (-8 = not applicable) 
Other 
21. Was subject adopted?     1 = Yes  0 = No 
21a. If yes, how old was subject when he/she was adopted? ___ ___ (-8 = not applicable) 
22. Has social services ever been involved with subject?  1 = Yes  0 = No 
22a.If yes, how old was subject? ___ ___ (0 = at birth; -8 = not applicable) 
23. Any history of physical and/or sexual abuse over lifetime? 
0 = No  1 = Yes, Physical 2 = Yes, Sexual 3 = Yes, Both 
23a.  If yes, how old was subject? ___ ___ (0 = at birth; -8 = not applicable) 
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23b.  If yes, describe: __________________________________________________ 
24. Has subject ever lived outside parental household for greater than 6 months?  
1 = Yes  0 = No 
24a. If yes, age at first residency outside parental household greater than 6 months: ___ ___ (-8 = n
24b.Detailsoutsideresidency:_________________________________________________ 
25. HANDEDNESS 
Which hand does the subject use to write?  to cut with a knife?  to comb his/her hair?  to 
play sports?  Does the subject do anything with the (opposite) hand 
 1 = Right  2 = Left   3 = Mixed 
26. HORMONAL/FERTILITY ISSUES (if male, check here ____: skip to Strauss and Carpenter 
Outcome Scale on following page) 
26a. Date of onset of last monthly period __ __/__ __/__ __ (including if currently 
menopausal) 
26b. Is subject currently on birth control pills?    1 = Yes 0 = No 
26c. Is subject currently undergoing estrogen replacement therapy? 1 = Yes 0 = No 
26d.  Is subject currently pregnant?    1 = Yes 0 = No 
26e.  Date of pregnancy test:                                                                          __ __/__ __/__ __ 
26f.  Type of test:                                                                    1 = urine 0 = blood 
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